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Abstract 
Recently, phytochemicals have attracted attention due to their antioxidant, haemo-protective 
and anti-cancer properties. As compared to most Food and Drug Administration (FDA) 
approved cancer therapeutic drugs, phytochemicals have shown specificity towards cancer 
cells and have little or no adverse effects on healthy cells. One such phytochemical is 
Thymoquinone (TQ), a quinone based constituent in volatile oils of Black cumin. Its anti-
oxidant and anti-inflammatory effect has been reported in various disease models including 
encephalomyelitis, diabetes, asthma and cancer. While TQ has been shown to affect cancer 
cell motility and migration, a distinct signalling pathway responsible for this effect has yet to 
be identified for the effect of TQ on motility and migration of cancer cells. The focus of this 
research was to elucidate the mechanism by which TQ interacts with the extracellular 
adhesion proteins of the cells involved in the motility, migration and cancer metastasis. The 
results revealed that TQ at low concentrations reduces the expression of e-cadherin (E-cad) 
which is a transmembrane protein responsible for cell-cell adhesion. The reduction of E-cad 
in cancer is a hallmark of epithelial to mesenchymal transition (EMT). During EMT, 
epithelial cells lose their adhesion proteins to detach from tumour, exhibiting mesenchymal 
phenotype, entering the blood, and metastasize to its secondary target site. 
This poses a risk under in vivo scenario since TQ exhibits low bioavailability in the body and 
undergoes rapid elimination. Hence, the effective concentration of phytochemicals in the 
body are often much lower than when encountering the target cells in vivo. To address the 
issues of degradation, low bioavailability and low solubility of TQ in aqueous media, nano-
based solutions were utilised. Three different types of nanoparticles were used to improve the 
therapeutic efficacy of TQ viz. dendrimers, nanosuspension and polymer-amino acid gold 
composite. All three nano-based systems showed significantly higher therapeutic efficacy 
xx 
 
compared to pristine TQ with increased toxicity due to increase in levels of reactive oxygen 
species and change in mitochondrial membrane potential level. 
In order to understand that the pro-cancerous effect of TQ was due to its lower concentration; 
an experiment was conducted in which the nanoformulations were titrated on the basis of 
viability of TQ at a sub-lethal concentration. The results from this experiment suggest that 
low concentration of TQ is responsible for activation of EMT in cancer cells which can be 
potentially resolved by the use of different nanoparticulate based formulations to increase its 
therapeutic efficacy against breast cancer.  
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Chapter 1: Literature review 
1.1 Cancer 
Cancer is a disease caused by an uncontrolled division of abnormal cells in the body. Cancer 
is also sometimes referred to as neoplasm, which is defined as a new and abnormal growth of 
tissues in some parts of the body [1-3].  
The word cancer was coined by the Greek physicians, Hippocrates and Galen, and originates 
from the Greek word Karakinos, which means crab. It then evolved to the Latin term cancer, 
which also means crab or now refers to a malignant tumour [4, 5].  
In Australia, lung, prostate, colorectal, stomach and liver cancers are the most common types 
of cancer in men; while breast, colorectal, lung, uterine, cervix and stomach cancers are the 
most common among women  [6]. 
1.1.1 Current statistics 
According to the estimation by the GLOBOCAN project, a World Health Organisation (WHO) 
council initiative, in 2012, there were 14.1 million new cases of cancer, 8.2 million cancer 
deaths and 32.6 million people were suffering from cancer (within 5 years of diagnosis), 
worldwide [1].   
In Australia, it was estimated that 130,466 new cases of cancer would be diagnosed by 2016. 
Every 1 in 2 males and 1 in 2 females will be diagnosed with cancer by the age of 85 years. 
During the census studies in 2013, it was found that there were 44,108 cancer related deaths in 
2013, which is estimated to rise to 46,880 by 2016 [7].  
According to this estimation,  cancer is spreading at a rapid rate and eventually will be the 
leading cause of death in the world [6].  
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1.1.2 Types of Cancer 
Cancer can be classified according to the organ and tissue type it is found in, and then based 
on grade, followed by stage. By these methods, there are four main types [1, 7, 8]: 
 Carcinomas, which arise in epithelial tissue that is found in the internal and external 
linings of the body. There are 2 types of carcinomas – (i) Squamous cell carcinomas, 
which develop in the squamous epithelium of organs, including the skin, bladder, 
oesophagus, and lung and (ii) Adenocarcinomas, which develop in glandular structure in 
epithelial tissue.  
 Sarcomas, account for less than 10% of all cancers, and arise from connective tissues that 
are found in bones, tendons, cartilage, muscle, and fat.  
 Leukaemia is cancer of the blood that originates in the bone marrow due to which they 
are also known as liquid cancers since bone marrow is the site for blood production. During 
the cancerous stage, the bone marrow produces excessive amounts of immature white 
blood cells that are not functional, and in turn weakening the immune system.  
 Lymphoma refers to cancers which develop in the lymph system. Unlike leukaemia, they 
are solid in state and develop at the lymph nodes in different parts of the body. They can 
be classified into two types as (i) Hodgkin’s lymphoma or (ii) Non-Hodgkin’s lymphoma 
depending on the presence of Reed-Strenberg cells.    
Once a cancer is classified on the basis of organ or tissue type, it is further graded from 1-4 on 
the basis of increasing abnormalities of cancer cells [9].  
Cancers can be also be individually differentiated on the basis of their stage. The commonly 
used method is based on tumour size (T) that includes increasing tumour size from T1- T4 , the 
degree of the spread or the node involved in the cancer (N) N1- N4, and finally on distant 
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metastasis (M) where M0 signifies no distant spread and M1 signifies the spread to secondary 
site [7, 10].    
1.1.3 Causes of cancer 
The causes of cancer are not very well defined as yet, but there are a number of reasons that 
have been attributed for cancer. Some of the proven risks include genetic instability, alcohol 
consumptions, smoking tobacco, poor diet, low physical activity and exposure to radiations 
[10-12].  
1.2 Methods of Cancer therapy 
The scenario of different approaches for cancer therapy has changed drastically in last few 
decades. The most common methods of treating cancer include surgery, radiation therapy and 
chemotherapy. Cancer therapy can be prescribed either before surgery (neoadjuvant 
chemotherapy) or after surgery (adjuvant therapy). In neo adjuvant therapy, the patient is 
treated with the chemotherapy/radiation/ hormone therapy before any surgery, so as to reduce 
the size of tumour, making it operable. Alternatively, adjuvant or additional therapy can be 
administered after surgical removal of the tumour, to ensure the remaining infected area is 
cleared of cancer cells. This procedure is performed in order to prevent the spreading or 
recurrence of the cancer [9]. Since none of the treatments are sufficiently effective to cure 
cancer by themselves, most treatment regimens involve a combined approach to increase the 
efficacy of the therapy.   
1.2.1 Surgery 
Cancer surgery is one of the oldest methods for cancer therapy. One of the main reason for 
surgery is to remove cancerous cells or tumour at the site within the body in order to prevent 
the spread of cancer to other parts of the body and restore the bodily functions back to normal 
[9]. Surgery is used for few different purposes which include[7]: 
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a) Diagnostic: Surgery is initially used to perform a biopsy in the patient, which is sent to 
a pathologist for cancer diagnosis. However, for determining the size or the amount of 
spread, staging is used, in which the doctor collects the lymph node near to the cancer 
for analysis.  
b) Primary surgery/ Tumour removal: This type of surgery is most commonly used for 
removal of tumour completely to keep the surrounding cells healthy. Some of the side 
effects include pain, tenderness, scars and swelling.  
c) Debulking: In this process, the surgeon is unable to remove the complete tumour or 
cancerous cells from the target site in order to avoid a large impact on the body. The 
remaining part of the tumour or cancer is treated with techniques such as radiation or 
chemotherapy.   
d) Palliation: A tumour or cancerous sites in the body causes a number of side effects 
such as pain, bowel blockage and excessive bleeding. Hence, palliative surgery is used 
to relieve these side effects.  
 
1.2.2 Radiotherapy 
Radiotherapy involves the use of high ionizing electromagnetic radiations in order to shrink 
the tumours and eradicate cancer cells by preventing their growth and proliferation at the 
target site. 
Radiotherapy can be delivered in two ways [6, 10, 13]: 
a) External radiotherapy:  Radiation beams are generated from a large external machine, 
also known as a linear accelerator, which is responsible for targeting the radiation 
towards a particular area of the body.  
b) Internal radiotherapy: A radiation source is placed within the body, such as the 
intravenous introduction of a radioactive substance. 
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1.2.3 Chemotherapy 
Chemotherapy is administered in cycles for short periods of time followed by recovery time 
which can last for up to 6 months. At every treatment the chemo dosage travels through the 
blood stream to its target site, where rapidly dividing cells either get arrested or turn apoptotic 
or necrotic in nature and eventually get destroyed. However, there are a number of side effects. 
The drugs cannot precisely distinguish between cancerous and normal cells thereby killing both 
populations. Hence, chemotherapy cycles include recovery periods in between treatments 
lasting for 3-6 months. Some general side effects include hair loss, loss of appetite, mouth 
sores, nausea, vomiting and low cell blood count [9, 14].  
The most commonly used drugs are anthracyclines (doxorubicin/Adriamycin® and epirubicin) 
and taxanes (such as paclitaxel/Taxol®) in combination with 5’ fluorouracil (5-FU). The 
different kinds of drugs include [10]: 
 Doxorubicin 
 Docetaxel 
 Paclitaxel 
 Platinum based drugs (cisplatin and carboplatin) 
 Capecitabine (Xeloda®) 
 Vinorelbine  (Navelbine®) 
 Gemcitabine (Gemzar®) 
 Liposomal doxorubicin (Doxil®) 
 Albumin-bound paclitaxel (Abraxane®) 
 Eribulin (Halaven®) 
 Mitoxantrone 
 Ixabepilone (Ixempra®) 
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Some other side effects can vary depending upon the kind of drugs being used and include 
neuropathy, permanent heart damage (cardiomyopathy), hand-foot syndrome and also 
increased risk of leukaemia due to bone marrow damage. Even though these drugs show such 
harmful effects, there are currently no effective alternatives for cancer treatment [7, 13, 15].   
1.3 Drawbacks of current cancer therapies 
 Current anticancer chemotherapy suffers with following major drawbacks: 
a) Non-specificity:  A number of anticancer drugs available in the market are very effective at 
destroying cancer cells, but they cannot distinguish a cancerous cell from a normal cell. Hence, 
non-selectivity of anticancer drugs becomes an issue, leading to systemic toxicity and severe 
side effects, impacting the livelihood of the patient with increase in after care. Repeated doses 
of chemotherapy and radiation have the highest impact on the immune system leading to 
common illnesses, such as common cold and pneumonia [3, 9, 16]. Approximately 67% of 
deaths in cancer patients are due to infections arising as a result of the compromised immune 
system [1].   
b) Drug resistance: With increase in anticancer drug usage, the cells have started to develop 
resistance against multiple drugs. This includes altered apoptosis regulation, increased DNA 
damage repair, alteration in metabolism, under expression of topoisomerase II or 
topoisomerase II gene mutations, decreased uptake of water-soluble drugs and increased 
energy-dependent efflux of hydrophobic anticancer drugs. The efflux is due to over expression 
of glycoproteins involved in the transport of drugs outside the cells. Due to this efflux, patients 
need to be exposed to high dosages of anticancer drug [17, 18].  
c) Inability to cross protective lining of tissues: Anticancer drugs cannot cross the protective 
lining of some tissues. For example, the brain is well protected by the blood brain barrier (BBB) 
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and anticancer drugs are unable to cross the BBB to provide therapeutic effects in brain cancer 
[19, 20].  
d) Aggregation or precipitation due to poor aqueous solubility: Most anticancer drugs 
developed recently such as taxanes and platinum based drugs have shown strong cytotoxicity 
against cancer cells. However, the major drawback of these anticancer compounds is 
lipophilicity and poor aqueous solubility which forms an obstacle for further formulation 
research and development for clinical purposes [4, 9, 21].  
e) Short circulation half-life: Most commonly used anticancer drugs have a short half-life in 
the blood, even though they have strong therapeutic efficacy. Hence the amount of drug to be 
administered to the patient must be frequent, to improve the efficacy of the dosage. With the 
increase in dosage of the chemotherapeutic drugs, it would affect the overall well-being of the 
patient [3, 22].    
1.4 Complementary or alternative therapies: 
In order to avoid the issues surrounding current conventional therapies, people have started the 
use of complementary therapies or have opted for alternative therapies. According to literature 
there has been a rise in the use of complementary and alternative medicine (ECM) in Australia 
and around the globe [3, 10]. Complementary therapies are used as aides to the conventional 
therapies, by providing supportive measures to control the side effects, control symptoms and 
enhance overall well-being of the patient. Some examples of complementary therapies include 
healing, meditation, aromatherapy, relaxation, reflexology, etc. [23].  Alternative therapies, on 
the other hand, are used as a replacement to conventional treatments. Alternative therapies 
include modern techniques (such as homeopathy and ozone therapy) and traditional techniques 
such as naturopathy, acupuncture, traditional herbal medicines that include traditional oriental 
medicine, Ayurveda etc. These alternative remedies are known for their therapeutic effects on 
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a plethora of acute and chronic disorders which range from the common cold to various types 
of cancer. Since the last few decades, scientists have identified the active constituents in the 
plant based remedies as phytochemicals [11, 24, 25].  
1.5 Phytochemicals 
The word phytochemical can be divided into two as “phyto” and “chemical”. The word phyto 
is derived from a Greek word which means plants, hence they are chemicals derived from 
plants. These include flavonoids, carotenoids, phenolic compounds and sulphur rich 
compounds and an estimated five thousand phytochemicals have been detected for treatment 
of different diseases including cancer (Figure 1.1).  
 
Figure 1.1 Effect of phytochemicals at different stages of cancer. Phytochemicals have 
usually more than one target which makes them useful at every different stages in cancer 
development. Diagram adapted with permission from Gonzalez-Vallinas et al, 2013,[24]. 
 
They have attracted attention due to their roles in the regulation of a variety of physiological 
functions, such as regulation of enzymes involved in cell metabolism and providing a defence 
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mechanism against microbial and viral infection. Epidemiological studies suggest that intake 
of fruits, vegetables and spices on regular basis can act as a source of various phytochemicals 
to cure diseases such as diabetes, cancer and inflammation [3, 25-30]. 
 The biological activity of medicinal plants is due to the presence of these bioactive 
phytochemicals as components. They are produced by the plants as secondary metabolites. 
Most of these secondary metabolites are of little importance to the plants as they are a by-
product of metabolic activities occurring within the plants. Sometimes they are required for 
specific function at certain developmental stages of the plant growth (Table 1.1). At times, they 
are also produced in response to damage or for protection against the environment conditions. 
For example resveratrol in red grapes and quercetin in onions can protect against environmental 
pathogens. Other functions include protection against environmental stress, rapid plant wound 
healing and as colouration of flowers, seed development and scent emission. Hence they are 
often produced only in small amounts [11, 16, 25, 28, 30]. 
  
10 
 
Table 1.1 List of some bioactive components in plants and their putative mechanism of action 
in cancer cells 
Dietary 
source 
Bioactive 
components 
Putative mechanisms of action References 
Red grapes, 
red wine 
Resveratrol Modulation of cell signalling 
pathways, inhibition of angiogenesis, 
induction of apoptosis and type II 
programmed cell death 
[3, 12, 31-33] 
Turmeric Curcumin Induction of detoxifying enzymes, 
inhibition of COX-1, COX-2, iNOS, 5-
LOX and PLA2 enzymes, induction of 
apoptosis and down-regulation of β-
catenin 
[34-37] 
Green tea Catechins 
(EGCG) 
Modulation of cell signalling 
pathways, inhibition of COX-2 and 
iNOS enzymes, anti-angiogenic, 
induction of apoptosis 
[38-42] 
Chilli peppers Capsaicin Modulation of cell signalling 
pathways; inhibition of phase I 
enzymes 
[3, 24, 30] 
Ginger [6]-Gingerol Modulation of cell signalling 
pathways,  anti-proliferative  and 
induction of apoptosis 
[43-46] 
Onions Quercetin Modulation of cell signalling 
pathways, inhibition of COX-2, 5-
LOX, 12-LOX enzymes 
[47-49] 
Honey Caffeic acid 
phenethyl ester 
Induction of phase II enzymes, 
inhibition of inflammation 
[50-52] 
Broccoli Isothiocyanates Induction of phase II enzymes, 
modulation of cell signalling pathways, 
induction of apoptosis 
[25, 53-57] 
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1.6 Thymoquinone (TQ) 
Thymoquinone (TQ) is a phytochemical obtained from a well-known spice with various 
common names such as Black Seed, Black Cumin, Kalonji, Kalajira, and Roman Coriander [8, 
43, 58-79].  The seeds are sourced from an annual herb, Nigella sativa which is native to the 
regions bordering the Mediterranean Sea, Western Asia and India. It belongs to the botanical 
family Ranunculaceae [58, 59, 64, 80, 81]. These seeds comprise of amino acids, 
carbohydrates, fixed and volatile oils, alkaloids and saponins to name a few. In 1963, El-
Dakhakhny isolated a crystalline substance from the volatile oil, which was identified as 
Thymoquinone (Figure 1.2). Ghoseh et al., (1998) demonstrated that this component is the 
major constituent (30-48%) of Nigella sativa [82]. A number of studies have tested this 
compound for its therapeutic effect in many diseases, including cancer, inflammation, 
atherosclerosis, diabetes and sepsis [82, 83, 89] 
  
Figure 1.2 Seed and flowers of Nigella sativa (on the left) and chemical structure of 
thymoquinone  
Figure 1.3 represents a timeline showcasing the major milestones in the history of TQ since its 
discovery.  The first formulation of N. sativa was documented in 1650 B.C. in Turkey during 
where the seeds were mixed with different bee product such as honey, wax, pollen and jelly. 
Since then, they have been of religious significance in many civilisations including Egyptian 
and Greek. The Greek physician Hippocrates showed the applicability of N. sativa oils for 
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treating digestive and liver disorders [58, 65]. Another Persian physician reported its use for 
stimulatory effects in 980 A.D.  During 570-630 A.D. Prophet Muhammad had recognised the 
black seed as a powerful agent to cure most diseases except death [59, 66]. 
Thymoquinone is one of the chief constituent extracted from N. sativa along with the other 
components that include dithymoquinone (DTQ), thymohydroquinone (THQ) and thymol 
(THY). Its molecular weight is 164.2 g/ mol and the chemical formula is C12H10O2. The seeds 
also contain essential components such as carbohydrates, fat, vitamins, minerals, proteins and 
essential amino acids.   
 
Figure 1.3 Time-line illustrating 4,000 years of Nigella sativa use in medicinal formulations 
which includes from the first documented N. sativa formulations made with honey in the 
Middle Hittite Kingdom to the explosion of published, scientific research over the last 
decade. Adapted from S. Banerjee et al. with permission [83] 
1.7 Thymoquinone as an anticancer agent 
1.7.1 Anti-proliferative effect of TQ 
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A promising strategy for cancer treatment is to attack the hyper-proliferating cells that give rise 
to the tumour. With respect to TQ, proliferation of mouse neoplastic keratinocytes was 
inhibited by as about 50% at non-cytotoxic concentrations. Later on it was found to inhibit 
various kinds of cancers which include glioblastoma (U87 MG and T98G, M059K and M059J), 
breast adenocarcinoma (multi-drug-resistant MCF-7/ TOPO, MCF-7, MDA-MB-231 and BT-
474), leukaemia (HL- 60 and Jurkat), lung cancer (NCI-H460 and A549), colorectal carcinoma 
(HT-29, HCT-116, DLD-1, Lovo and Caco-2), pancreatic cancer (MIA PaCa-2, HPAC and 
BxPC-3), osteosarcoma (MG63 and MNNG/HOS) and prostate cancer (LNCaP, C4-2B, 
DU145 and PC-3) [14, 28, 40, 43, 58, 60, 63, 65, 66, 71, 77, 78, 84-108]. However, TQ showed 
little effect on the non-cancerous cells such as mouse fibroblasts, prostate epithelial cells, 
normal human intestinal cells and normal human lung fibroblast [58, 60, 95, 96]. The results 
from the above studies indicated that TQ only affects an array of cancerous cells while having 
insignificant effect on the normal cells. 
1.7.2 Effect of TQ on cell cycle   
Recent reports have demonstarted    the impact of TQ on the cell cycle progression by arresting 
the cancer cells at different stages of cell cycle. Thymoquinone has demonstrated G0/G1 phase 
cell cycle arrest in papilloma carcinoma cells and HCT116 human colorectal carcinoma cell 
line and G1 to S phase arrest in LNCaP prostate cancer cells and in acute lymphoblastic 
leukaemia [109, 110]. A number of studies have also shown G2/M phase arrest in mouse 
spindle carcinoma cell, MNNG/HOS human osteosarcoma cells and in doxorubicin resistant 
breast cancer cells [62, 111, 112]. A sum total of all the above results suggest that TQ’s mode 
of action involves the cell cycle arrest as an important event in the anticancer mechanism.  
1.7.3 Apoptotic effect of TQ 
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Apoptosis is the process of programmed cell death in multicellular organism.  A multicellular 
organism is made up of highly organized community of different types of cells. The numbers 
of cells in the community are tightly regulated by two processes viz. controlled rate of cell 
division and controlled death rate [28, 113]. The controlled process is mediated by a cascade 
of intracellular proteins. When disruption of the programmed cell death occurs, it gives rise to 
uncontrolled proliferation of cells, which gives rise to cancer cells. Hence, apoptosis is a major 
event that is targeted by the chemotherapeutic drugs to cure cancer. Thymoquinone is known 
for its pro-apoptotic effect in cancer cells [52, 57, 60, 61, 63, 65, 66, 84, 96, 99, 114]. The 
induction of apoptosis in the cells occurs in numerous ways through various molecular targets 
and pathways. Thymoquinone induces apoptosis via both pathways viz. p53-dependent and 
independent pathway [76, 115]. The involvement of p53 was noted in some recent studies 
which showed resistance to TQ in case of apoptosis in HCT116 human colorectal cancer cells 
and p53-null myeloblastic leukaemia HL-60 cells [84, 116]. However, El-Mahdy et.al found 
TQ to induce apoptosis in p53-null HCT116 cells, simultaneously activating caspase 8, 9 and 
3 as well as Bax/Bcl ratio. This finding suggested a p53 independent pathway for induction of 
apoptosis by using a caspase inhibitor z-VADFMK [117].  
Further studies have observed the effect of TQ not only by p53 but also of other pathway such 
as signal transducer and activator of transcription 3 (STAT3), Phosphatase and Tensin homolog 
(PTEN) [77, 92]. Thymoquinone suppressed the proliferation of MCF-7/DOX, doxorubicin 
resistant breast adenocarcinoma cells, but also upregulated the PTEN expression levels in the 
cells [14]. Thymoquinone has also been able to show apoptosis in multiple myeloma cells, 
activating the caspases and PARP cleavage [118-120]. Inhibition of both constitutive and IL-6 
inducible STAT3 phosphorylation was also observed in U266 cells.  
Thymoquinone has accounted for apoptosis by supressing Tumour necrosis factor (TNF-alpha 
via NF-ĸb regulation) which includes IAP1, IAP2, Bcl-2, Bcl-xL, Survivin, and COX-2 cyclin 
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D1, c-myc, DΨM and vascular endothelial growth factor in KBM-5 in human myeloid cells 
[121]. The human umbilical vein endothelial cells and glioblastoma cells showed inhibition of 
VEGF-dependent ERK and Akt activation [20, 43, 73]. Thymoquinone simultaneously 
upregulated Bax and down regulate Bcl-2 and Bcl-xL, Mucin-4 in human pancreatic cells while 
suppressing the proteins survivin, XIAP and Mcl-1 via a proteosomal pathway [61, 98, 122]. 
Thymoquinone mediated apoptosis seen in SiHa (human cervical squamous carcinoma) cells 
was more potent compared to cisplatin [66, 123]. The highlights mentioned from the above 
recent literature suggest that TQ has an ability to induce apoptosis in the cancer cells through 
not only different targets but also through activation of different pathways.  
1.7.4 Oxidative Stress 
Almost all cancer cells are known to have elevated levels of reactive oxygen species [124]. The 
increased reactive oxygen species (ROS) are one of the causes that increase, to some extent, 
tumour development and cancer progression. A delicate balance of ROS levels is maintained 
intracellularly for cancer cell function [125, 126]. It appears to be a challenge for any novel 
therapeutic drug for targeting the intracellular levels of ROS. The strategy involves interference 
with the ROS levels so that the ROS-induced tumour progression is halted along with initiation 
of apoptosis.  
Recent studies have revealed initiation of apoptosis in the cancer cells via the ROS production, 
rather than anti-oxidant/anti-inflammatory effects [4, 8, 46, 58, 85, 87, 101, 102, 106, 114, 122, 
127-133]. Thymoquinone has exhibited increased levels of ROS leading to induction of 
apoptosis in primary effusion lymphoma cells [106]. It was further confirmed by addition of a 
strong antioxidant which reverses the effect of TQ, and promotes Akt activation, thereby 
preventing apoptosis. Another study conducted in DLD-1 human colon cancer cells showed 
the same TQ mediated apoptosis due to change in ROS levels and also supported that it could 
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be reversed upon use of N-acetyl cysteine [134]. In fact, one study showed that the application 
(pre-treatment) of N-acetyl cysteine could save prostate cancer cells (C4-2B) from TQ 
mediated apoptosis. In addition to this, Alhosin et al. established that TQ has an ability to 
generate ROS metabolites, which in turn activates mitochondrial membrane potential loss in 
Jurkat cells [84]. An interesting observation by Zubair et al. (2013), suggested that TQ like 
most phytochemicals can act as either an antioxidant or a pro-oxidant when used at low 
concentrations in in vitro studies. The author suggest that it acts as a pro-oxidant in presence 
of transition metal ions such as copper. Hence, TQ leads to increase or decrease in oxidative 
stress due to their dual mode of action [101]. The reason behind TQ’s ability to act as an 
antioxidant or pro-oxidant was suggested to be dependent upon the variations of TQ into 
hydroquinone or semiquinone in any given cell type [80, 82, 135-138]. Altogether the results 
from different studies indicate that ROS levels play a critical role in the TQ mediated apoptosis 
which leads to either anti-inflammatory/ anticancer activity.  
1.7.5 Synergistic effect of TQ with chemotherapeutic drugs  
Chemo-treatment for cancer is mostly based on single drug administration. Localized treatment 
involves surgery and/or radiation to remove the bulk of the tumour, followed by treatment with 
cytotoxic chemicals that kill both fast dividing tumoral and normal cells [7]. Many years of 
clinical research involving in vitro and in vivo models have shown that cytotoxic drugs when 
combined are more effective since they exhibit synergistic effects (such as combinatorial or 
additive effects) [132]. The rationale behind the use of two or more cytotoxic drugs as 
chemotherapy is to administer drugs such that they use different mechanism to kill the tumour 
cells thereby reducing the likelihood of drug resistance in the cells and improve its cytotoxic 
effect. A synthetic, natural or a biological agent that has an ability to reduce or delay the 
occurrence of malignancy at different stages in cancer is called chemopreventive agent. 
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However combining chemotherapy drugs can greatly increase adverse effects to normal cells 
[14].  
This synergistic effect was also observed in the case of TQ, when combined with certain 
chemotherapeutic agents. Thymoquinone was found to increase the cytotoxicity when 
combined with cisplatin on non-small cell lung cancer cells (NCI-H460) [90]. Combination 
with TNF, paclitaxel or doxorubicin showed higher toxicity towards KBM-5 cells [97]. Earlier 
exposure of TQ to the pancreatic cells (HPAC and BxPC-3) could increase the cytotoxic effect 
of gemcitabine and oxaliplatin. It also leads to down regulation of Bcl-xL, survivin and XIAP 
proteins with increase in the amount of caspase-3 activity. However, it had no effect on human 
pancreatic ductal epithelial cells [61, 133]. Thymoquinone was able to increase the induction 
of apoptosis in U266 when combined with thalidomide and bortezomib [120, 139]. 
Thymoquinone also demonstrated sensitization across MCF-7 cells and T47D and increased 
cytotoxicity against radiation [86]. The above findings suggest that TQ could complement the 
chemotherapeutic drugs to achieve greater therapeutic effect in a clinical setting.  When TQ 
was combined with 5-fluoro uracil for the treatment of the gastric cancer cells, it showed 
increase in apoptotic cells and also a regression pattern of growth was seen in gastric cell 
xenograft nude mice [105]. Thymoquinone was found to delay the growth of tumour cells in 
HCT116 cell xenograft mice and increased the induction of apoptosis shown by the TUNEL 
staining of tumour cells. In colon cancer induced by 1, 2 dimethyl hydrazine, it was found that 
TQ was able to reduce the number and size of aberrant crypt foci [140].  
1.8 Limitations of TQ in cancer therapy  
1.8.1 Solubility  
The solubility of a substance may be defined as the maximum quantity of a substance that may 
be dissolved in a solvent. It is a key factor that is necessary for a successful formulation of most 
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anticancer drugs required for delivery to the target in the body. Thus, it is a challenge to 
increase the solubility of the phytochemical /drug due to its structural and chemical properties. 
The TQ solubility in different solvents was extensively studied by Salmani et al [135]. 
According to them, TQ solubility ranged from 549-669 µg/mL in all aqueous solutions. They 
concluded that observed profile of aqueous solubility was good enough to maintain effective 
therapeutics level of in vivo studies. Even though the solubility was observed to be increasing 
up to 72 hours in water, it was not possible for them to determine a value in extreme conditions 
of acid and base [135]. One of the possible reason suggested, was due to chemical/physical 
instability of the TQ in these solvents as, it may interfere with soluble fraction of TQ. Hence 
to further understand this, degradation studies were necessary to check the production of 
various degradation products in each of the solvents.  
1.8.2 Stability and degradation of TQ 
The stability of TQ in aqueous solutions was evaluated in 0.1 N HCl solution (acidic) and at 
three different pH viz. 5, 7 and 4 of phosphate buffer solution. In order to determine the stability 
of TQ, high performance liquid chromatography (HPLC) was performed to investigate the 
degraded products after 96 hours. The residual concentrations in all the different solutions 
showed time dependent decrease in stability of TQ and the HPLC chromatograms showed 
decrease in the area under the peak, with simultaneous rise in new degradation peaks post 96 
hours. At acidic pH, TQ showed minimal amounts of degradation towards by-products [135].   
Studies on rate of degradation predicted that the TQ showed similar patterns of degradation in 
water and saline solutions but slightly higher in phosphate buffer solutions and the highest was 
seen in the alkaline phosphate buffer. This was also accompanied by increase in the number 
and the intensity of the degradation peaks. The R2 values suggested that, in acidic and basic 
conditions, TQ degradation tends to follow first order kinetics and that in pH 5, water, saline 
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and pH 7.4 followed second order kinetics. This means, the degradation of TQ in highly acidic 
and basic condition (0.1 N HCl and pH 9 respectively) depends upon the concentration of TQ, 
whereas in case of solutions of pH 5, water, saline, and pH 7.4 solution it depends upon 
concentration of TQ, pH or phosphate salts [135].  These factors play an important role in 
preparation of a successful drug formulation.  
Finally, it was concluded that degradation in aqueous media poses a major problem as it is not 
possible to exactly quantify the amount of TQ in a drug release study. Therefore, there is a need 
of a suitable media which offers least degradation in aqueous conditions for improvement of 
formulation.  
1.8.3 Photolytic degradation of TQ 
 Light plays a crucial role in the degradation of TQ. The study from Salmani et al. suggests that 
TQ is highly sensitive to light even for short period of exposure [135]. The results of their study 
suggest that almost all solvents showed 80% degradation of drug within 24 hours and 90% 
after 48 h. Shorter time points showed that rapid degradation < 70% occurs within 10 hours of 
incubation while following the second order kinetics which means that it is dependent on both 
the concentration and the type of solvent being used as well.  
Furthermore, the study claimed that to test the purity of TQ solution, UV-visible spectroscopy 
was the best method. The results indicated that the initial spectral analysis revealed a peak at 
257 nm which after 48 h incubation disappeared with rise of few more peaks at different 
wavelength other than 257 nm [135].  
Under dark conditions, it was noticed that there was no significant degradation of TQ when 
monitored in either presence of ethanol or dimethyl sulphate with water or buffer in ratio 1:1 
[135, 137-140]. This suggests the combination of either of the above mentioned would be a 
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good strategy for in vitro drug release studies for the formulation. However, all studies need to 
be performed in absence of light to avoid any photolytic degradation.  
1.9 Rationale: 
Recently, phytochemicals have attracted a lot of attention as being a natural source of 
antioxidants, chemo-protection and anti-cancer model drugs [141]. Thymoquinone is known 
to initiate apoptosis in several cancers such as prostate, breast, pancreatic, lung, etc. via 
different signalling pathways including PI3K/Akt and JAK-STAT [60, 102, 117, 120, 142-
146]. The two effects that are well explored with respect to TQ in cancer are apoptosis and its 
antioxidant activity [8, 87, 104, 106-108, 120, 146-150].  
The current study is based on two major objectives that are unexplored with regards to TQ.  
Firstly, TQ has been reported for decreased cell motility and migration in cancers cells. 
However, the exact mechanism by which TQ affects cell motility and migration is not well 
understood. Hence, this study was undertaken to unravel the pathway by which TQ affects 
motility and migration at cellular level.  
Secondly, even though the therapeutic activity of TQ has been promising, there are some major 
drawbacks which hinder its biological activity and its bioavailability, such as poor solubility 
and rapid degradation in aqueous environment. This hampers the formation of successful 
therapeutic formulation of TQ. In order to obtain an efficacious formulation of TQ, it should 
remain protected until it reaches its target site and promote its uptake into the tumour cells. 
This problem may be solved with the help of a nanoformulation, allowing increased solubility 
in an aqueous environment. 
A nanoformulation would prevent the degradation of TQ, which in turn would improve the 
pharmacokinetic profile of the compound. This would also protect the compound from the 
harsh aqueous environment, thereby, preventing degradation before reaching the target site. 
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These nanoformulations can also help to improve strategies for higher distribution and 
targeting for anti-tumour treatment. Nanocarrier can be designed for easy penetration into the 
cells by targeting them in a way that they selectively enter the tumour or into the stromal 
compartments of the cells.  
Another advantage is the small size of the nanocarriers, which can increase the payload of the 
compound, thereby playing a pivotal role in improving the efficacy of the treatment. They can 
also be designed to release the compound only under some kind of stimulus. For example the 
most popular property of the tumour environment that has been exploited involves pH change. 
Nanocarriers can be designed such that they release their payload only under certain pH 
conditions.  
Hence, the focus of this study is to use different nanoformulation with TQ, to test the increase 
in therapeutic efficacy by increasing its solubility and stability. 
1.10 Thesis outline 
Chapter 1 comprises of introduction and review of the literature related to the aim of this 
thesis. An in-depth discussion with regards to need for phytochemicals such as TQ in cancer 
therapy is provided. The chapter also includes the recent advances and efforts done to 
understand the anticancer effects of TQ. 
Chapter 2 sheds light on a new biochemical pathway in order to understand the anticancer 
properties of TQ and in particular, to study the effect of low concentration of TQ in in vitro 
conditions.  In order to addresses the problems due to low bioavailability and stability of TQ, 
use of 3 nanoformulations (3 different types) were proposed.  
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Chapter 3 includes the use of a 1st type of nanoformulation also known as nanosuspension. 
The nanosuspensions of TQ were characterised and evaluated for the increase in stability, 
thereby, increasing efficacy against human breast cancer cells. 
In Chapter 4, a dendrimer based nanoformulation was introduced to encapsulate TQ to 
improve its aqueous solubility and stability. The phytochemical loading and release studies 
were also performed to investigate the improvement of efficacy in the cells. 
Chapter 5 aims at exploring the self-assembled pluronic based polymeric micelles 
functionalized by a gold and amino acid nanoparticles as a drug delivery vehicle. The chapter 
investigates the effect of TQ encapsulated within the nanoformulation and study the possibility 
of increase in efficacy of the phytochemical. 
Chapter 6 comprises of a comparative analysis of the all three nanoformulations, in order to 
choose the nanoformulation with best TQ efficacy. At the same time, it also discusses the effect 
of nanoformulations on pro-cancerous effects of TQ  
Chapter 7 summarises and concludes the findings in this thesis along with some future 
prospects for continuation of this work.  
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Chapter 2: Thymoquinone mediated lysosomal degradation of E-
cadherin in breast cancer cells 
2.1 Introduction 
Breast cancer is the most common malignant disease in the western world. Although there has 
been a decrease in the rates of breast cancer due to early diagnosis by mammographic scanning 
and adjuvant therapy, chemotherapy itself has a wide range of acute and long term side effects 
which substantially affect the quality of patient’s life [1, 2]. Hence the focus is now shifting 
towards alternative therapies such as using metabolites from natural products. This alternative 
way of chemotherapy involves the use of natural (herbal) plant metabolites with lesser or no 
side effects. Thymoquinone (TQ, 2-isopropyl-5-methyl-1, 4-benzoquinone) is a bioactive 
component obtained from volatile oil of black cumin (Nigella sativa) and is a commonly used 
spice in traditional Middle Eastern medicinal formulations. 
Recent studies in relation to the effect of TQ in different cancers have exhibited TQ as having 
antioxidant, anti-inflammatory, anti-neoplastic, anti-metastasis and anti-angiogenesis 
properties in vitro as well as in vivo [1-4] . Thymoquinone has generated great attention due to 
its pleiotropic nature i.e. it is specific to only the tumour cells without harming the non-
cancerous (epithelial) cells [5]. Modern research claims TQ as a pro-apoptotic agent against 
several types of cancers such as prostate, breast, pancreatic, lung, etc. activating signalling 
pathways including PI3K/Akt and JAK-STAT [1, 6-12]. The two effects that are well explored 
with respect to TQ in cancer are its antioxidant activity and apoptosis [13].  Thymoquinone has 
been also reported for decreased cell motility and migration in cancercells. However, the exact 
mechanism involved is not well understood.  
Epithelial to Mesenchymal transition (EMT) is an integral process of development, wound 
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healing, stem cell behaviour, and a pathological contributor to cancer progression [14]. It is 
essential for changing the nature of cancer cells from non-metastatic to metastatic and is the 
phenomenon in which epithelial cells undergo biochemical changes and differentiate to give a 
motile mesenchymal phenotype. The process of EMT involves reorganization of the 
cytoskeletal architecture comprising of actin cytoskeleton and focal adhesion points which in 
turn is responsible for the stability of cadherin-catenin complex (CCC).  The rearrangement of 
the CCC  causes reduction in epithelial properties and an enhancement in mesenchymal 
properties such as increased migratory capacity, resistance to apoptosis and increased 
invasiveness [15]. EMT is achieved by the degradation of underlying basement membrane and 
the formation of a mesenchymal layer, causing the cells to drift away from the epithelial layer 
in which it originated and settle down at other favourable locations within the body [16]. From 
recent literature, it is known that adherens junctions (AJs), which are essential for preserving 
the integrity of the basal lamina of epithelial tissues, play a critical role in tissue formation and 
developmental stages of  organisms as well as maintaining cell polarity and integrity [14]. 
During diseases such as cancer, the adherens junctions play a major role in deciding its nature 
i.e. non-metastatic to metastatic.  
A major component of the adherens junctions are the cadherin proteins. Classical cadherins 
such as E-cadherin (E-cad) are transmembrane glycoproteins, which are necessary for Ca2+ 
dependent cell-cell adhesion and are among the traditional markers of an epithelial phenotype.  
Being a transmembrane glycoprotein, E-cads have an extracellular as well as intracellular part. 
The extracellular region of E-cad spans the cell surface and is usually involved in homophilic 
recognition by E-cad present on adjacent cells [17]. The intracellular cytoplasmic tail of E-cad 
binds to different cytosolic proteins like the  α and β catenins to form the CCC (Figure 2.1),  
which provides an anchorage to form stable cell to cell contact and are linked to fundamental 
intracellular processes like the actin cytoskeleton, cell signalling and vesicular trafficking [18].  
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Figure 2.1 Illustration of cadherin-catenin complex in association with actin cytoskeleton  
Loss of E-cad has been implied in disruption of stability at adherens junctions at any given 
time in the cell. Destruction of AJs due to degradation of E-cad  has not only been associated 
with loss of cell polarity leading to cell death, but this also activates the migratory machinery 
leading to EMT [16, 19]. Loss of E-cad releases the β-catenin, and this loss can be due to 
different reasons in the cell, like increase in the calcium influx leading to proteasomal 
degradation of the glycoprotein. Previous studies suggest that intracellular fate of internalized 
E-cad leads to its sorting for either degradation or recycling, which is a crucial step, as it 
eliminates existing AJs or re-deploys E-cad in formation of the new junctions. 
β-catenin, when separated from E-cad, translocates to the cytoplasm and is eventually 
transported to the nucleus where it acts as a transcription factor in the canonical Wnt-signalling 
pathway [18]. Here it combines with T-cell factor/lymphoid enhancer factor (TCF/LEF) to 
form a transcriptional complex which up regulates the transcription of its target genes.  Most 
of the targets of the β-catenin transcriptional complex are anti-apoptotic and lead to cell 
differentiation and proliferation, which in the case of tumours, make them more aggressive in 
nature [18]. 
The current study has been undertaken to understand the role of TQ and its potential as an anti-
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cancer agent. Although there is no shortage of studies conducted that establish the toxicity and 
pro-apoptotic effects of TQ towards cancer cells at high concentrations [2-4, 6-8, 10, 12, 20-
31], the exact mode of action of TQ remains elusive at sub-toxic concentrations. In real time, 
TQ concentration reduces as it has to overcome several barriers in the body in order to reach 
its target site. In an attempt to shed light on the biochemical pathways of TQ activity, this 
chapter will outline in clear and concise steps, the difference in the effects of low concentration 
of TQ against high concentrations of TQ on cell toxicity.  
A coherent rationale has been postulated that sequentially links TQ with E-cad degradation and 
resultant β-catenin up regulation. The objectives underling this chapter are: 
1. Determining the effect of TQ in an array of cancer cells.  
2. Assessing the effect of sub-lethal concentrations of TQ on cancer cells. 
3. Delineating mechanistic aspects of TQ mediated in vitro cellular responses via 
reorganization of cytoskeleton. 
2.2 Materials and Methods 
2.2.1 Materials 
Dulbecco's Modified Eagle Medium (DMEM), Penicillin-Streptomycin 10,000 U/mL, TryplE 
Express, Phosphate Buffered Saline (PBS), 5-(and-6)-carboxy-2',7'-difluorodihydrofluorescein 
diacetate (carboxy-H2DFFDA), Rhodamine 123, Ultrapure DNase and RNase free water, MTT 
purchased from Life Technologies, Mulgrave, Victoria, Australia. A stock solution of 1 mM 
carboxy-H2DFFDA was prepared in ethanol and stored under nitrogen, at -20°C and in the 
dark. A stock solution of 1 mg/mL Rhodamine123 was prepared in methanol and stored at 4°C 
and in the dark. Foetal Bovine Serum (FBS) was purchased from Interpath Services, Heidelberg 
West, Victoria, Australia. Paraformaldehyde was purchased from Electron Microscopy 
Sciences, The Patch, Victoria, Australia. Working solution of 4% was prepared in PBS and 
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chilled to 4°C. Bovine serum albumin (BSA), dimethyl sulphoxide (DMSO), cell culture 
ethanol, propidium iodide (PI), Triton-X 100, phosphate buffer saline (PBS) tablets, cell culture 
grade chloroform and isopropanol were purchased from Sigma-Aldrich, Castle Hill, New 
South Wales, Australia. Cell culture wares such as 25 cm2, 75 cm2, and centrifuge tubes were 
purchased from Corning, Castle Hill, New South Wales, Australia. Tissue culture grade 6 well 
plates and 24 well plates were obtained from Nunc, Scoresby, Victoria, Australia. Pipette tips 
and eppendorf tubes were purchased form Eppendorf, North Ryde, New South Wales, 
Australia. The Primary antibody were purchased from Santa Cruz Biotech Pty Ltd which 
include: Mouse monoclonal E-cadherin (1:150 dilution); Rabbit polyclonal β-catenin (1:200 
dilution); all the secondary antibodies conjugated with Alexa 488 (1:500) and Alexa 594 
(1:700) and Lysotracker (Red-DND) were purchased from Thermofisher Pty Ltd., Australia. 
2.2.2 Cell viability assay 
The basic principle of the assay involves the conversion of the MTT (3-(4, 5-dimethylthiazol-
2-yl)-2, 5-diphenyltetrazolium bromide), tetrazolium salts into purple formazan crystal by 
viable cells in culture. The formazan crystals are solubilized by the addition of acidified 
isopropanol or acidified sodium dodecyl sulphate and the resultant colour is measured in a 
spectrophotometer between 570-600 nm. The absorbance correlates directly with cell 
number. Briefly, the 10,000 cells were seeded in a 96 well plate, incubated overnight and 
treated with 5, 10, 25, 50, 100 µM TQ for predetermined time period of 24, 48 and 72 h for 
each cell line. A 10 µL aliquot of MTT (5 mg/mL) was added to each well and further 
incubated at 37°C for 4 hours. The medium was replaced with acidified isopropanol and plate 
absorbance was measured at 595 nm in Perkin-Elmer UV-vis spectrophotometer. The 
selected cell lines were treated with MTT, further to study at three different time points viz. 
24, 48 and 72 hours.  
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2.2.3 Cell Morphology studies 
The qualitative technique to confirm the cell viability assay is obtaining pictures at different 
time point after the introduction of the drug. MCF-7 and MDA-MB-231 cells (50,000 cells) 
were seeded in each well of six well plate. After overnight incubation, cells were treated with 
different test concentration and snapshot using phase contrast microscope fitted with Nikon 
CCD camera were taken at different time points.  
2.2.4 Immunofluorescence 
Immunofluorescence studies were used to determine protein levels in the MCF-7 cells. The 
cells were seeded in six well plate containing coverslips. They were treated with different 
concentrations of TQ and fixed after the stipulated time using 4% paraformaldehyde. The 
coverslips were washed twice with ice-cold PBS (1X) and subjected to either permeabilisation 
or blocked (without permeabilisation) with 2% bovine serum albumin (BSA) with 250 µL 
foetal bovine serum FBS. After the blocking step, the coverslips were treated with appropriate 
dilutions of primary antibody in 2% BSA/FBS for 1 h in humidified chamber. The coverslips 
were washed with chilled 1X PBS (containing 2% BSA/  
BSA) at least 3 times, followed by incubation with flourophore-tagged secondary antibody for 
30 min to 1 h in a dark humidified chamber. The coverslips were washed 2-3 times with PBS 
and then treated with Alexa Fluor 488® phalloidin (1:40), a high-affinity filamentous actin (F-
actin) probe, for 20 min in dark humidified chamber at room temperature.  The coverslips were 
thoroughly washed with PBS and mounted onto a glass slide using Prolong gold antifade 
mounting media containing Hoechst 333628 (nuclear stain).  Finally the coverslips are sealed 
and stored at 4°C.  
The confocal micrographs were imaged using Nikon confocal laser scanning microscope and 
analysed further using NIS Elements 4.0 (Advanced research) and a 60 X oil objective lens 
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(Nikon) with an NA of 1.4 was used. Images were obtained using the Nikon CFLSM. Data 
shown are representative of three independent experiments.  
For the Lysotracker Red-DND 1 mM probe stock solution was diluted to the final working 
concentration (50 nM) in the growth medium (DMEM). For the LysoTracker® probes, the 
recommended procedure involves the cells grown on the coverslip were added the pre-warmed 
(37°C) probe-containing medium. Cells were incubated for 30 minutes at 37°C. The loading 
solution was then replaced with fresh medium and cells were fixed and then regular 
immunostaining protocol was followed as above. 
The primary antibodies purchased from Santa Cruz Biotech Pty Ltd include: Mouse 
monoclonal E-cadherin (1:150 dilution); Rabbit polyclonal β-catenin (1:200 dilution); 
secondary antibodies conjugated with Alexa 488 (1:500) and Alexa 594 (1:700) Lysotracker 
Red DND (1 mM Stock) were purchased from Thermofisher Pty Ltd., Australia. 
2.2.5 Intracellular Ca2+ Measurements using fura-2 AM dye 
Activation of MCF-7 cells was assessed by monitoring variations in calcium levels using a 
Flexstation. Briefly, MCF-7 cells were seeded at 1 x105 cells/mL (0.2 mL/ well) in a 96-well 
plate for 24 h. Ratiometric measurement of calcium was achieved after loading the cells for 30 
min with the membrane-permeant fluorescent indicator FURA-2AM (Molecular probes). Dye 
loading medium constituted with 0.25% Pluronic  F-127 (Molecular Probes) and 10 μM 
FURA- 2AM in flex assay buffer (137 mM NaCl, 5.4 mM KCl, 1.2 mM CaCl2 2H2O; 1 mM 
MgSO4.7H2O; 0.3 mM NaH2PO4 H2O; 0.3 mM KH2PO4; 10 mM HEPES) pH 7.4. Effectors 
to be tested were prepared in parallel in flex buffer and automatically added onto the cells 
during the assay. Measurements were typically carried out for 300 secs with a measurement 
every second. To obtain a baseline, fluorescence signals (excitation 340/380 nm - emission 510 
nm) were measured for 30 sec in flex assay buffer prior to a washing step and addition of 
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compounds on the cells. Intracellular free calcium concentration (nM) was estimated using the 
equation of Grynkiewicz,  
[Ca2+]i =
Kd β (R − Rmin)
(Rmax − R)
 
 where Kd (apparent dissociation constant) was determined at 224 nM for FURA-2AM, β being 
the fluorescent ratio (EGTA 380 nM), R is the fluorescent ratio measured upon effector 
stimulation, Rmax provided by adding 0.1% Triton X-100 on the cells after a washing step and 
Rmin by the subsequent addition of 10 mM EGTA. Adenosine triphosphate (5 μM) was used as 
a positive control in the experiment. Each effector was tested in triplicates. 
A separate drug plate was prepared and loaded in the Flex station (Molecular devices Pty Ltd) 
for further steps. The results obtained were analysed using the Soft Max Pro 5.4 (Molecular 
devices Pty Ltd).  
2.2.6 Flow cytometry 
The extracellular protein level of E-cad after TQ treatment to MCF-7 cells was determined 
using flow cytometery analysis. Briefly, MCF-7 cells were washed and dislodged using EDTA-
sodium buffer from the 6-well plate and pelleted in eppendorf tubes. A detergent free medium 
was used for the dislodgement of cells in order to prevent damage on extracellular protein on 
the cells. Dislodged cells were washed and resuspended in FACS (Fluorescence activated cell 
sorting) buffer, followed by blocking with 10% FBS. The cells were treated with primary 
antibody mouse monoclonal E-cad (1:150 dilution) dissolved in the 2% BSA and incubated in 
a humid chamber for 1 h with respect to the E-cad antibody (1 µL in 200 µL suspension). After 
the designated time for incubation, the cells were washed at least 3 times. The cells were then 
resuspended in 200 µL of FACS buffer and treated with secondary antibody (Alexa Fluor 488: 
goat anti-mouse FITC (0.5 µL in 200 µL suspension). Finally the cells were washed and 
resuspended in FACS buffer.   
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Data was collected using BD FACS Canto II flow cytometer (Beckton Dickinson, USA). The 
data obtained for flow cytometer was analysed with help of FlowJo Software (Version 
10.0.8r.1, LLC, USA). The number of events (cells) used for analysis were 20,000 cells. The 
computational analysis was performed using FlowJo Software (Version 10.0.8r.1, LLC, USA. 
A flow cytometry dot-plot was plotted using forward v/s side-scattered. The MCF-7 cells were 
then gated to include 10,000 events for each of the treatments (untreated, 10 μM and 25 μM 
) to further plot the histogram 
2.2.7 Chromatin Immuno Precipitation Assay (ChIP) Assay 
Cells were fixed with 1% formaldehyde for 10 min. Cross-linking was arrested by adding 
glycine (0.125 M) for 5 min at room temperature. The cells were subsequently harvested in 
SDS lysis buffer (0.5% SDS, 100 mM NaCl, 50 mM Tris-Cl pH 8.1, 5 mM EDTA pH 8.0, 
protease inhibitor mixture Complete (Roche) and 1 mM phenylmethylsulfonyl fluoride 
(PMSF). Nuclei were pelleted and resuspended in IP buffer (2 volumes SDS lysis buffer:1 
volume Triton-X buffer (100 mM Tris-Cl, pH 8.6, 100 mM NaCl, 5 mM EDTA pH 8.0, 5% 
Triton X-100)). The lysates were sonicated using BIORUPTOR sonicator for 12 cycles of 30 s 
and centrifuged at maximum speed. The sheared chromatin was diluted to 1 mL with IP buffer 
and pre-cleared with salmon sperm DNA/recombinant protein A-agarose (Thermo Scientific) 
for 2 h. One per cent of the sample was used as the input control and the remaining precleared 
chromatin was incubated overnight with 10 μg by incubation with salmon sperm DNA/protein-
A agarose (50% slurry) and centrifugation. The samples were diluted with IP buffer to obtain 
the desired concentration (between 10 -50 µg per IP) with 1% of lysate was used as total 
control. The diluted chromatin lysate (1mL) was added to each safe lock tube containing the 
primary antibodies: β-catenin (dilution 1:20) and rat immunolglobulin (1: 1000). These safe 
locktubes were then incubated overnight on a shaking rotor at 4°C. The bead pellets were 
washed in low- or high-salt conditions (0.1% SDS, 1% Triton X-100, 2 mM EDTA pH 8.0, 
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20 mM Tris-HCl pH 8.0, and 150 mM (low)/500 mM (high) NaCl). The beads were then 
washed once with LiCl buffer (0.25 M LiCl, 1% NP-40, 1% Na-deoxycholate, 1 mM EDTA 
and 10 mM Tris-HCl pH 8.0) followed by two washes with Tris-EDTA. Elution buffer (0.1% 
SDS, 0.1 M NaHCO3) was added to the samples and the cross-linking was reverted by 
incubation at 65 °C overnight. Samples were incubated 1 h at 37 °C with RNAse A (Sigma) 
and 45 min at 50 °C with proteinase K (Ambion, Life Technologies). The DNA was purified 
using Minelute PCR Purification Kit (Qiagen) and then amplified by qPCR 
2.2.8 Real-time quantitative Polymerase Chain Reaction (qPCR) 
Real-time quantitative PCR (qPCR) was performed using Fast SYBR® Green Fast Gene 
Expression Assay on a 7500 Fast Applied Biosystems instrument. The experiment was set up 
as per manufacturer’s instructions. Samples were prepared as shown in Table 2.1. A total of 10 
μL reaction mix was added to each well of a 96 well reaction plate, sealed and centrifuged 
briefly before loading into the instrument. Samples were run with two holding stages at 50°C 
for 2 minutes, 95°C for 10 minutes followed by 45 cycles of 95°C for 15 seconds and 60°C for 
1 minute. Samples were in triplicates and three independent experiments were performed. Gene 
expression of CdK2 is expressed as fold change or delta delta threshold cycle (ΔΔCT), the 
housekeeping genes GAPDH were used for normalization of qRT–PCR data, unless otherwise 
stated. 
Table 2.1: Sample preparation for real time qPCR for 10µL reactions 
Component Volume (µL) 
Fast SYBR® Green Master Mix (2✕) 
Forward and Reverse Primers‡ 
DNA  (25ng)  
Ultrapure RNase, DNase free water 
5.0 
1.0 
2.0 
2.0 
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2.3 Results 
2.3.1 Thymoquinone shows variable cytotoxicity in cancer cells: 
Initial investigation was based on dose dependent cytotoxicity of TQ on different cell lines 
which include Human lung cancer cells (A549), human breast cancer cells (MCF-7 and MDA-
MB-231) and Prostate cancer cells (PC-3). To determine the dose response, the cells were pre-
treated with different test concentrations of TQ in each cell line for 24 hours. MTT assay was 
used to determine the cell viability which was an endpoint assay. The assay depicted that the 
lung carcinoma cells (A549) showed marginal toxicity as they were highly resistant to the TQ 
concentration up to 100 µM. (Figure 2.2). The cell viability percentage at the highest 
concentration showed only about 20 % decline in cell population. The prostate cancer cells at 
lower concentration show proliferation of cells but with steady increase in dosage, it eventually 
lead to cell death. Amongst the four cell lines tested MCF-7 and MDA-MBA-231 cells (Human 
breast adenocarcinoma) showed the most sensitivity to TQ. The graph (Figure 2.2) suggests 
that TQ has been most effective in MDA-MB-231 followed by MCF-7 cells. Both the cells 
lines did not show much decline at the sub-toxic concentrations (5 and 10 µM) but there was a 
drastic decrease in the cell viability at higher concentrations causing almost complete clearance 
of cancer cells at 100 µM. Hence, breast cancer was chosen for further to study the effect of 
TQ.  
In order to understand the effect of TQ phenotypically in both breast cancer cell lines, cell 
morphology assay was performed. Both cell lines viz. MCF-7 and MDA-MB-231 were 
subjected to TQ treatment with three different concentrations viz. after 12 h.  Figure 2.3 below 
depicts MCF-7 cells untreated as well as spread with sharp edges. This is an indication of 
healthy cells. The cells treated with TQ showed change in morphology with increase in TQ 
concentration. 
49 
 
  
Figure 2.2 Dose dependent cytotoxicity of TQ in different cells lines viz. Human Lung cancer 
cells (A549), Human breast cancer cells (MCF-7 and MDA-MB-231), and prostate cancer cells 
(PC-3) after 24 h exposure. Cell viability was determined by MTT assay and reported as 
percentage of viable cells relative to control. The data was presented as mean ± standard error 
(SE) of three independent experiments. Significant differences were determined by ANOVA on 
Microsoft Excel. The level of statistical significance was *p < 0.05 and **p < 0.001. The 
statistical significance was calculated between PC-3 and MDA-MB-231 since the viability 
profile appears to be similar in the graph. 
At 25 µM, the sharpness at the edges of the cells disappears making them appear with smooth 
edges. However, the cells are still well spread and adhered to the surface of a 6 well plate. This 
suggests the effect of TQ in extracellular region of the MCF-7 cells. Along with change in 
morphology it was also noticed that as soon as the media containing TQ was administered to 
the MCF-7 cells, they would immediately dislodge from bottom of the plate without any change 
in morphology of the cells. This suggests an indication that TQ has direct effect on the 
extracellular proteins of the cells. This effect was not visible in MDA-MB-231 cells. Upon 
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treatment of TQ in media the cells rounded off completely, thereby detaching from the surface 
of well.  
 
Figure 2.3 Cell morphology studies on (a)MCF-7and (b)MDA-MB-231, treatment with 
different test concentrations of TQ 
Hence, there was a clear indication that TQ affects the adhesion properties of MCF-7 cells. It 
was chosen for further studies, as MCF-7 cells are slow migrating cells with higher expression 
of adhesion proteins. However, before initiating further studies, the right concentration needed 
to be chosen for investigating the effect of TQ at sub-toxic concentration.  
In order to further understand the effect of TQ, MCF-7 cells were subjected to TQ for longer 
exposure periods (24, 48 and 72 h) presented in Figure 2.4. At 24 h time point the cells showed 
a steady decline in the viability. Higher concentrations such as 50 and 100 µM were the most 
effective concentration where the cell viability was negligible. However, this was not the case 
in the longer exposure periods. In case of lower concentration there were not any changes in 
the cell viability at 48 h. Most recovery of cells was noticed at the 72 h time point only. The 
result from the graph below reveals the recovery of cells at lower concentration of TQ after 72 
h incubation. There is slight increase in viability at 5 µM, that further lead to a significant rise 
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at 10 µM by 22.3%. There was rise in viability at each of the concentrations of TQ, suggesting 
an overall recovery of cells in case of 72 h time point.  
The aim of this project was to explore the mechanistic aspect of TQ in MCF-7 cells. Hence, 
the cytotoxic assay was performed to determine the sub-toxic concentration required to study 
the mechanistic aspects of TQ without killing the MCF-7 cells. The 10 µM concentration was 
chosen as the ideal concentration for further studies, because at 10 µM, the cell showed low 
toxicity at 24 and 48 hr along with significant recovery 72 hours.  At this concentration, it 
would also help to understand the effect of low bioavailability of TQ in in vitro conditions.  
 
Figure 2.4 Dose and time dependent toxicity of TQ on MCF-7 cells. Cell viability was 
determined by MTT assay and reported as percentage of viable cells relative to control. The 
data was presented as mean ± standard error (SE) of three independent experiments. 
Significant differences were determined by ANOVA on Microsoft Excel. The level of 
statistical significance was *p < 0.05 and **p < 0.001 
In order to improve the understanding about the changes in the morphology of the MCF-7, the 
next task involved the investigation of cytoskeletal framework of the cells.  Therefore, TQ 
treated cell were fixed and  probed for  actin and vinculin, the main cytoskeletal proteins 
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responsible for cellular shape, adhesions and migration. In order to stabilise the cell shape as 
well for migration, actin forms a circumferential network (CAF) around the inner periphery of 
the cells. These CAF are in turn linked to the cadherin catenin complex (CCC) stabilising them 
at the periphery. Upon TQ treatment, disruption of circumferential actin network is noticed in 
the MCF-7 cells (Figure 2.5) leading to reorganization of actin filaments.  
 
Figure 2.5 Confocal micrograph depicting the E-cad aggregation due to TQ treatment at 
sub-toxic concentration (10 µM) in MCF-7 cells. The cells are fixed and stained with E-, 
vinculin (red) and DAPI for DNA (blue) after 2 h incubation with TQ. (Scale bars: 50µm) 
When closely observed the focal adhesion points also seem affected with TQ treatment. The 
focal adhesion points were highlighted using the vinculin antibody. The red spots towards the 
outer perimeter indicate the presence of Vinculin in the untreated sample which tends to reduce 
at the edges in MCF-7 cells when treated with TQ. This reduction and reorganization of the 
focal adhesion points is an indication of cells in migratory state [18, 32]. 
Probing the cytoskeleton shed some light on the morphological changes occurring in the cells 
at sub-toxic concentration in terms of cytoskeleton reorganization. Furthermore, it is essential 
to decipher the effect of TQ in the MCF-7 cells with respect to the adhesion protein especially 
the CCCs as the CAF is found to be disrupted. Further exploration on TQ’s mode of action on 
cell-cell adhesion complex (such as CCC) will help to develop an understanding behind 
detachment of cells from the substrate immediately after the TQ treatment.   
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2.3.2 Thymoquinone affects the cytoskeleton and focal adhesion in MCF-7 cells 
Observations from the previous experiment revealed changes in the cytoskeletal architecture 
along with diminishing circumferential actin filaments (CAF) upon treatment of TQ. The 
presence of CAF requires the CCC to be located at the periphery. Hence it was necessary to 
investigate the involvement of CCC during TQ treatment. During treatment, the first exposure 
to the TQ containing media is encountered by extracellular adhesion proteins in the cells. As 
mentioned in the introduction, the CCC’s consists of the intracellular cytoplasmic tail of E-cad 
bound to the actin cytoskeleton via α and β-catenin.  
As part of the initial investigation the levels of E-cad were checked qualitatively by subjecting 
MCF-7 cells to sub toxic concentration of TQ for 2 hours after which they were immunostained 
with E-cad antibody. The confocal images captured revealed a substantial decline in the E-cad 
levels (in green) at 10 µM (Figure 2.6).  
 
Figure 2.6 E-cad is expressed as cell surface marker. In the figure, green highlighted 
boundary shows presence of E-cad in MCF-7 cells. While scale bars in left and middle 
micrograph correspond to 50µm, in right image it is 20µm 
However, the cells at 25 µM, did not show much decrease in the level of E-cad. The results 
obtained clearly suggest that at sub-toxic concentration TQ might have a different mode of 
action.  
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In order to further validate the above result, qualitative studies were performed at both 
concentrations using flow cytometery. The cytometric graph (Figure 2.7) below represents the 
mean fluorescence intensity which consistently depicted two distinct populations of MCF-7 
cells that includes E-cad expressing population (positive) and E-cad absent /low level 
population (negative). A significant decline in the mean fluorescence intensity of E-cad 
following the TQ treatment was visible at 10 µM, but this was not the case at higher TQ 
concentration (25 µM).  
 
Figure 2.7. The graph obtained by flow cytometery analysis represents the mean fluorescence 
intensity of E-cad in MCF-7 cells after treatment with TQ along with an untreated control 
(black) , 10 μM treatment (green) and 25 μM TQ (magenta) 
The quantitative and qualitative results together validate that decline in E-cad is due to TQ 
especially at low or sub-toxic concentration. However, it is important to check if the cells were 
still viable with decrease in E-cad. Hence the next essential experiment was conducted to check 
cell viability. Before the cells were fixed, they were stained with Hoechst live cell stain. The 
dye selectively stained only the live cells. The results from the confocal micrographs (Figure 
2.8) below suggest that at 10 µM, the viability was not affected; however there was distinctive 
decline in the E-cad levels in the treated cells. 
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Figure 2.8 Confocal micrographs of MCF-7 cells along with 10 μM TQ. The cells were 
stained with Hoechst stain for determination of population viability (Scale bars: 50µm)  
2.3.3 Thymoquinone mediated lysosomal degradation of E-cad  
Internalization of E-cad is followed by either recycling back to the lateral membrane or shuttled 
to the lysosome  [33]. In order to investigate the fate of E-cad, MCF-7 cells were treated with 
10 µm TQ and then stained with E-cad antibody and LysoTracker for 15 minutes.  Figure 2.9 
shows the three micrographs, one for each individual channel/ filter (FITC or Texas red) and 
an overlay image. The E-cad was highlighted in green and the lysosomes were highlighted in 
red. The overlay image obtained by merging the two individual images depicted an 
orange/yellow signal (co-localization). This is an indication of E-cad being localized within the 
lysosomes. Hence, suggesting the fate of E-cad to be degraded in lysosomes. 
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Figure 2.9 Localization of E-cad in the untreated and TQ treated (10 μM TQ) cells depicted 
in the confocal micrograph for MCF-7 cells. After 2 h of TQ treatment the cells were fixed 
and stained with E-cad antibody (green) and lysotracker (red). (Scale bars: 50µm) 
From the above results, it can be established that TQ treatment at low/ sub-toxic concentration 
might lead to degradation of E-cad in the cells. Degradation of E-cad in cancer cells is a 
hallmark of epithelial to mesenchymal transition (EMT). E-cad degradation leads to the 
destruction of cadherin-catenin complex consisting of detachment from actin filaments and 
separation of components such as β-catenin and α-catenin that are stabilised by E-cad. Upon 
degradation of E-cad, β-catenin is known to relocate into the cytoplasm and either degrade or 
by localising in the nucleus, act as a transcription factor [18, 34-36]. The latter process helps 
in facilitating the survival or EMT in cells.  
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2.3.4 TQ mediated E-cad degradation is associated with calcium influx 
Loss of E-cad is triggered by the calcium induced calcium influx resulting in translocation of 
β-catenin from the cell-cell contacts to nucleus. 
Fura-2 AM assay was performed in order to investigate whether TQ could interact with calcium 
in the cellular context as E-cad expression has been reported to be linked with changes in 
intracellular calcium levels [36].  Fura-2 AM assay was performed in order to investigate 
whether TQ could interact with calcium in the cellular context as E-cad expression has been 
reported to be linked with changes in intracellular calcium levels [36, 37]. Fura-2 AM is a dye 
which enters the cell and measures changes in cytoplasmic calcium levels. Cells were grown 
in a calcium containing buffer, and then treated with different concentrations of TQ (1, 10, 25 
µM) [38] and adenosine triphosphate (ATP). The mean fluorescence intensity of Fura-2 AM 
was measured at every second up to 50 seconds immediately after TQ treatment. 
The graph below (Figure 2.10) depicts a delayed increase in intracellular calcium levels at 10 
µM and 25 µM TQ (starting from 10 sec onwards). In contrast, ATP showed an immediate 
rapid increase in calcium signals. 1 µM TQ concentration was comparable to the control sample 
which showed no change in intracellular calcium levels. Calcium influx, which is a response 
to an increase in the calcium levels outside the cell (as caused by the calcium buffer), can be 
due to two possible reasons.  First, an instantaneous influx can occur from the cell's own stores 
as this can be visualized by the addition of ATP which activates the calcium channels or it can 
be a delayed calcium influx which results from the entry of calcium ions across the plasma 
membrane [38]. As can be seenin Figure 2.10, presence of TQ showed a gradual increase 
instead of the instantaneous influx whereas control and 1 µM TQ did not show any significant 
influx in calcium levels. Hence, presence of 10 µM TQ has undoubtedly increased in 
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extracellular calcium influx, which is consistent with reports that stated the increase in 
extracellular influx, associated with destruction of cadherin-catenin complex [36, 39]. 
 
Figure 2.10 Calcium responses to TQ treatment in MCF-7 cells. ATP was used as a positive 
control for calcium influx assay.     
2.3.5 TQ triggers the translocation of β-catenin into the nucleus and transcription of 
Cyclin dependent Kinase 2 (CdK2)    
In order to investigate the translocation of β-catenin, Chromatin Immuno Precipitation (ChIP) 
assay was performed on MCF-7 cells. After the treatment of TQ (10 µM) the cells were fixed 
at different time point viz. 2 h and 8 h. In order to take into account a delay in the response to 
TQ, an 8 h time point was selected. The R IgG (human immunoglobulin generated in rabbit), 
was used as a negative control meaning it shows little or no response to the treatment in the 
cells. A small amount of response is observed in the graph (Figure 2.11) below which is 
considered as noise because most IgG antibodies are not obtained from true pre-immune serum 
from the same animal in which the specific antibody was raised.  
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Figure 2.11 Fold change in expression of CdK2 at 2 h and 8 h with respect to TQ treatment 
at 10 µM. The RIgG were used as negative controls 
CdK2 is a well-known target of β-catenin and the Figure 2.11 represents the fold change in 
expression of CdK2 in presence and absence of TQ. The increase in expression corresponds to 
increase in CdK2 gene transcription level; indirectly suggesting an increase in β-catenin levels 
in the nucleus. The results suggested, highest nuclear localization of β-catenin was observed at 
2 h time point. According to literature, β-catenin is a transcription factor with multiple target 
genes that is stabilised by CCCs [15, 18]. The ChIP assay involves the probing of β-catenin 
bound chromatin complex. The chromatin from this complex is separated and is quantitated 
using target (CdK2) for qPCR. The function of CdK2 is well established as a cell proliferator 
in normal cells [38]. The higher expression of CdK2 is known as trigger to uncontrolled 
proliferation of cancer cells. The β-catenin being a transcription factor has CdK2 as its target 
during its localization in the nucleus [36]. This provided an insight into the mode of action for 
TQ. At low concentration of TQ, the E-cad complex that stabilizes β-catenin is dismantled and 
it eventually relocated into nucleus increasing the transcription of CdK2. This aberrant 
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expression of CdK2 has been labelled as one of the main causes for initiation of phenomenon 
known as epithelial to mesenchymal transition (EMT) [15, 18]. 
2.4 Discussion 
Thymoquinone is a well-known quinone based natural phytochemical which forms an essential 
part of the traditional medicinal systems such as Unani and Ayurveda [2, 40]. Being pleiotropic 
in nature and finding its use in variety of ways for cancer and other therapies, it has attracted a 
lot of attention recently [4, 9]. Current literature claims TQ as a potential anticancer agent. 
However, there is very little understanding on the actual mode of action against cancer cells.  
The aim of this study was to elucidate the mode of action of TQ in breast cancer cells at low 
or sub-toxic concentrations. Present literature has always showed TQ against cancer cells at 
higher concentrations that were very effective under in vitro conditions. However, this does 
not represent a true scenario as many phytochemicals do not graduate as anticancer agents, due 
to low bioavailability in the cells. In the in vitro environment, TQ comes in direct contact with 
the target cells, however, in the in vivo environment, it has to cross several barriers such as cell 
membrane permeability, low pH in stomach and insufficient time for absorption, thereby losing 
its activity due to degradation, before reaching the target site and this in turn leads to low 
bioavailability of TQ at the target site.  
In this study, cytotoxicity assay on the arrays of cancer cells was performed in order to find the 
most sensitive cell line to TQ in a dose dependent manner. The aforementioned results showed 
that breast cancer cells viz. MCF-7 and MDA-MB-231 were most susceptible to TQ treatment, 
of which MDA-MB-231 was most sensitive. Both the cell lines originate from malignant 
adenocarcinoma and are obtained by pleural effusion [41, 42]. However, MCF-7 cells retain 
their characteristics of differentiated mammary epithelium and have the capability to grow in 
colonies in the form of domes [43]. The latter property makes it more resistant compared to 
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MDA-MB-231 cells that grow individually and do not from colonies or grow in domes, as well 
as having low amount of cell-cell adhesion proteins for attachment to the substrate. When TQ 
was administered in dose and time dependent manner, there was significant amount of recovery 
(by ~25%) in the MCF-7 cells at low concentrations of TQ after 72 hours of incubation. With 
higher concentrations the MCF-7 cell viability declined faster after 48 and 72 h, compared to 
24 h. The reason behind recovery at lower concentrations and   long exposure period could be 
due to the poor solubility, lower stability and photo- degradability of TQ that has been 
discussed in the detail in Chapter 1, section 1.8.   
As shown in the Figure 2.2, the most significant rise in MCF-7 cell viability was observed at 
10 µM concentration of TQ following 72 h incubation. Cell morphology assay at 10 µM 
concentration also showed significant changes in morphology of the cells. Change in cell 
morphology results from the reorganization of cytoskeletal proteins that determine its shape 
size and adherence to the substratum (Figure 2.3).  
According to Adam et al, cell-cell adhesion depends on clustering of cadherins and is 
associated with the organization of actin cytoskeleton [28]. The actin cytoskeleton was 
visualised by staining of fixed cells with a nuclear stain (DAPI) and F-actin fibres were labelled 
with conjugated phalloidin toxin. This highlighted the F-actin fibres supporting the 
cytoskeleton in confocal micrographs and revealed that at low TQ concentrations, disruption 
of circumferential actin network can be observed (i.e. conversion from F-actin fibre into its 
monomeric G-actin form) towards cell boundary (Figure 2.5). These results are in agreement 
with Bracke et al. who demonstrated that constitutive loss of the apical cortical actin ring results 
in components of the CCCs to get localized inside the intracellular vesicles [18]. The 
mechanism involves the conversion of cortin F-actin filaments (polymeric units) to G-actin 
(monomers). In this case, the cadherin components if intact move into Golgi vesicles where it 
gets recycled back to the surface of the cell or is degraded  in the lysosomes of the cells [44] . 
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The cells were also stained for cell adhesion protein known as vinculin. These results indicate 
that after treatment of TQ (sub-toxic) there was reduction and rearrangement of vinculin from 
the edge of the cells (Figure 2.5). The reduction of vinculin is usually associated with the poor 
adhesive properties of the cell as vinculin has long been identified as a protein involved in cell 
adhesion to substratum. Furthermore, studies by Hazan et al. (1997) discovered the association 
between vinculin and CCCs [45]. They suggested that vinculin plays a vital role in regulation 
of cadherin mediated cell adhesion by direct interaction with β-catenin. Another report 
regarding vinculin found that depletion of vinculin decreased the level of E-cad at cell surface 
via binding to β-catenin [45]. Hence these studies underline the dual role of vinculin in cell 
adhesion to substratum and cell–cell adhesion. From the above results, it is clearly observed 
that the actin cytoskeleton and vinculin, the two most important cytoskeletal proteins less 
expressed, which might be directly associated to CCCs (Figure 2.5). Hence, the effect of TQ 
needed to be examined on the CCC’s as they are in first line for exposure.   
 The results also reflected on the fact that E-cad’s adhesiveness is modulated by signalling 
events that dynamically influence vinculin binding to catenin. A well-established link between 
the loss of vinculin from adhesion sites and poor survival rates in patients suffering from 
cancers has been reported as well [17, 18, 28, 45, 46].    
Upon treatment with TQ, E-cad was found to be degraded at later time points, activating a 
signalling cascade. A similar kind of pattern was visible at protein level when tracked using 
immunofluorescence. Results obtained from measurement of E-cad quantitatively (confocal) 
and qualitatively (flow cytometery) helped to establish this fact (Figure 2.6 and 2.7). This effect 
was particularly seen at 10 µM TQ (sub-toxic) concentration.  
E-cad is a transmembrane protein existing as a complex which harbours the neighbouring cells. 
The loss of E-cad in cells is a hallmark of epithelial to mesenchymal transition (EMT) [47, 48]. 
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The process of EMT serves many different purposes in growth and maintenance of individual 
organism [14, 16, 19]. However, its effect in the cancer progression is vital for metastasis. 
Recent literature suggests that EMT can also contribute to resistance in chemotherapy [49-51], 
which further indicates that use of TQ as chemo-sensitizing agent is not preferable. 
Thymoquinone being quinone, are known to be highly reactive in nature. The mutagenicity of 
certain quinones has already been shown by formation of reactive oxygen species and others 
via their transformation to DNA-binding semiquinone free radicals. This not only makes 
quinones mutagenic but potentially carcinogenic, but paradoxically they are also well known 
anticancer agents. In a study on quinone based phytochemical, Shikonin was reported as 
anticancer and anti-inflammatory agent, showing initiation of EMT activities along with 
suppression of micro-RNA required for wound healing [51]. The Chapter 1 section 1.7 
discussed the dual nature of quinones especially TQ where it acts as pro-oxidant or antioxidant 
depending on the type of cell lines used i.e. it either generates reactive oxygen species or 
chelates the free radicals, respectively.   
The extracellular span of E-cad consists of two heavy chains associated with calcium ions [18, 
52]. However, this affects the CCC’s intracellular regions of E-cad such as β-catenin. The 
intracellular part of the transmembrane protein consist of the heavy chains connected to the 
p120, β-catenin and α-actinin attached to actin fibres providing the cell support and adherence 
to each other [18, 53, 54].  
The intracellular part of E-cad is known to stabilize β-catenin while simultaneously providing 
the cell a backbone to remain attached to the neighbouring cell. β-catenin is a known 
transcription factor facilitating the transcription of multiple gene targets. Unrestricted β-catenin 
localization in the nucleus eventually forms a complex with LEF/TCF family and initiates 
transcription [15, 44, 47]. Increase in β-catenin localization into the nucleus is directly related 
to increase in transcription of target genes. Chromatin immuno-precipitation assay (ChIP) was 
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employed to determine the levels of β-catenin in the nucleus and the cytoplasm, which revealed 
the presence of β-catenin in nucleus after the treatment with TQ (Figure 2.12). 
 
Figure 2.12 Schematic representation of TQ’s mode of action in MCF-7 cells at sub-lethal 
concentration (10 µM). Upon treatment at sub lethal concentrations of TQ, destruction of 
cadherin–catenin complex occurs, that leads to lysosomal degradation of E-cad and 
translocation of unrestricted β-catenin into the nucleus. It combines with TCF/LEF in the 
nucleus to form a functional transcriptional complex for the transcription of genes 
responsible for cell proliferation and differentiation (EMT)   
β-catenin affects transcription of various cell cycle proteins, a prominent member of which is 
cyclin dependent kinase (CdK2). Among several targets of β-catenin,CdK2 showed promising 
results. The CdK2 plays an important role in the apoptosis (programmed cell death) and DNA 
damage repair especially during cell divison [35, 36, 38]. Elevation in CdK2 levels leads to the 
activation from G1 to S checkpoint signalling. The G1 checkpoint plays an important role in 
preserving the genomic integrity of the cells along with prevention of S-phase transition for 
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cells with damaged DNA. CdK2 prevents the destruction of DNA leading to prevention of 
apoptosis [55]. The increase in the transcriptional level of CdK2 promotes proliferation, of 
cancer cells, thereby preventing cytotoxicity and in the case of cancer, promoting its 
aggressiveness (Figure. 2.12) [36, 39]. 
The extracellular span of E-cad consists of two heavy chains associated with calcium ions. 
Quinones are well known chelators [56, 57] and as mentioned in the results above, TQ showed 
association with the increase in the extracellular calcium influx (Figure 2.10). Hence this study 
proposes that TQ at sub-lethal concentration (10 µM) decreases E-cad levels via interaction 
with calcium ions on plasma membrane.    
2.5 Conclusion 
From the aforementioned results, it is reasonable to say that TQ may play a significant role in 
inhibiting cancer progression and metastasis in breast cancer cells at higher concentration but 
not at sub-lethal concentrations. At this point, TQ at sub-lethal concentrations depicts a pro-
cancerous profile in the cells, where the MCF-7 cells upon TQ treatment initiate proliferation 
instead of cell death. Furthermore, the decrease in E-cad expression can activate EMT, which 
would enable cells to migrate to secondary sites in the body; conceding cancerous cells the 
power to metastasize. 
In order to mitigate this issue, a suitable nanoparticle based approach for drug delivery to 
increase TQ’s stability may be chosen, which in turn would also enhance its therapeutic 
efficacy. In conclusion, our findings here not only help to contribute to the elementary 
understanding of TQ functions but also reveal novel strategic target to treat breast cancer.  
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Chapter 3: Nanosuspension of thymoquinone: formulation, 
characterization and biological evaluation 
3.1 Introduction 
From Chapter 2 of the thesis, it could be inferred that even though TQ showed promising 
cytotoxicity at higher concentrations, sub-toxic concentrations depicted a pro-cancerous 
profile. This effect makes the basis for hypothesis that the observed effect was due to lower 
stability of TQ in the medium. In order to address this, a nano-particulate system was suggested 
to be employed. This chapter deals with conversion of phytochemicals into novel 
nanoformulation in order to increase its stability and therapeutic efficacy.   
3.1.1 Nanosuspensions 
Nanosuspensions (NSPs) are sub-micron size colloidal form of dispersions of insoluble 
compounds that are stabilised using surfactants. Nanosuspensions have shown characteristics 
that include increase in stability and solubility which in-turn increases bioavailability [1, 2]. In 
addition, nanosuspensions can be used to disperse phytochemicals and/or drugs that are 
difficult to dissolve in both oil and water. The small particulate characteristics of 
nanosuspension have potential to change the pharmacokinetic profiles. Therefore, 
nanosuspensions offer exciting avenues to transform highly insoluble compounds which are 
often referred as “brick dust” during various drug discovery programs [3].  
The top down technology (Figure 3.1) encompasses disintegration of larger particles into the 
nanosuspension with the help of high pressure homogenization and milling methods whereas 
the bottom up technology involves assembling method to form the nanoparticles like 
precipitation, melt emulsification and micro emulsion [3]. The two basic methods of 
nanosuspension formulation techniques used in the following study are: precipitation and 
homogenization.  
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Figure 3.1 Schematic illustrating the bottom up and top down approach for synthesis of 
nanosuspension 
 
3.1.2 Precipitation 
This method is more commonly used method for preparation of nanosuspension from water 
insoluble compounds such as anticancer drugs and phytochemicals. It is a part of bottom-up 
technology that uses a drug already dissolved in an organic solvent [3, 4]. Firstly the 
phytochemical/drug is dissolved in the appropriate solvent. This mixture is then mixed with 
the hydrophilic medium (such as water) in which drug is insoluble in presence of a surfactant. 
This rapid process of addition of the mixture into the solvent and continuous stirring leads to 
quick supersaturating of the drug solution and it precipitates out of the solution to form ultra-
fine amorphous or crystalline drug particles (Figure 3.2). One important factor in this method 
is maintenance of low temperatures to prevent phytochemicals/drugs from degradation [4]. The 
nuclei formation and crystal growth for a stable nanosuspension formulation is also dependent 
on the temperature. For a stable formulation, high nucleation rates and low crystal growth are 
required for small particle size [5]. 
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Figure 3.2 Flow chart for preparation of drug nanosuspension using precipitation method   
 
3.1.3 Milling 
 
During the process of wet milling, powdered phytochemicals /drugs are subjected to milling 
media for nanoparticle production. This process involves a milling chamber that is charged 
with the milling media or glass or zirconium beads/balls enclosed in highly cross-linked 
polystyrene resin or ceramic-sintered aluminium oxide filled with drug, stabilizer and either 
water or suitable buffer. The chamber is rotated at a high shear rate to generate suspensions. 
The high shear forces are generated as an outcome of impaction of milling media with drug or 
phytochemical to convert into nano-sized particles [3, 6].    
 
3.1.4 Homogenization 
 
This technique involves three major steps: First, the phytochemical is dispersed in a stabilizer 
solution to form pre-suspension; after that, pre-suspension is homogenized by high pressure 
homogenizer at a low pressure sometimes for pre-milling, this is done in order to reduce the 
particle down to micron size. At the final step, the suspension, which contains drug and 
stabilisers is passed through a valve with a ultra-small orifice under high pressure (10-25 
cycles) to obtain desired particle size [3, 4]. 
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In order to overcome the hurdle of low stability and bioavailability, nanosuspensions of TQ 
were prepared using two different methods viz. precipitation and homogenization were 
employed for this study. The production of thymoquinone based nanosuspension requires 
stabilisers that play an important role in maintaining the stability of the formulation. The most 
important characteristic of nanosuspension is its small particle size, which also is responsible 
for its physical instability. They consist of small hydrophobic particles (drugs or 
phytochemical) dispersed in a hydrophilic medium.  Due to the large surface area of these 
nanoparticles, it results in high surface tension. This in turn results in increase in the free energy 
of the system which leads to aggregation or flocculation disrupting its stability [7]. Hence, in 
order to reduce this free energy on the nanosuspension, stabilisers are added. The different 
types of stabilisers include surfactants, polymers or a mixture of both. For example, Vitamin 
E/TPGS (D-α- Tocopherol polyethylene glycol succinate), sodium lauryl sulphate, Tween 80, 
hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), and polyvinyl 
alcohol (PVA).  
This study employs water soluble Vitamin E based stabiliser called D-α-tocopherol 
polyethylene glycol 1000 succinate that is obtained by the esterification of Vitamin E succinate 
with polyethylene glycol (PEG) 1000. It comprises of an amphiphilic structure consisting a 
hydrophilic polar head and a lipophilic alkyl tail. As mentioned above, it water soluble and has 
a low critical micellar concentration of 0.02% [7]. TPGS is well known non-ionic surfactant 
which has found its application in wetting, emulsification, detergency spreading and 
solubilisation [2, 3, 8].  
This chapter details the synthesis of two nanosuspension formulation of TQ. The thymoquinone 
based  nanosuspensions (TQ-NSPs) were characterized for the particle size, colloidal stability, 
in vitro release and its biological activity against breast cancer cells. 
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3.2 Materials and Methods 
3.2.1 Preparations of nanosuspension (Precipitation and homogenization method) 
3.2.1.1 Nanoprecipitation method 
A total of 25 mg of TQ was dissolved in 1 mL of ethanol and then dispersed in 0.25% w/v α-
Tocopherol polyethylene glycol 1000 succinate (TPGS) aqueous solution. The mixture was 
sonicated at 45% amplitude for 1 min followed by stirring at 1000 rpm for 3 h. The solution 
was filtered through 0.22 µm syringe filter. 
3.2.1.2 High pressure homogenization  
Thymoquinone (TQ) (25 mg) was initially dissolved in chloroform (1 mL) and added to 0.25% 
w/v TPGS aqueous solution. The dispersion was homogenised using high pressure 
homogenizer for 20 min and then the organic phase was removed by rotary evaporation at 100 
rpm and room temperature.  
3.2.1.3 Thymoquinone estimation in nanosuspension 
The drug content was determined by freeze drying both TQ-NSPs. Nanosuspensions were 
quickly pre-freezed using liquid nitrogen and then freeze-dried overnight at -50C and pressure 
< 1 mbar. An amount (5 mg) of lyophilized powder was dissolved in 1 mL of methanol and 
then absorbance was measured at 260 nm using a UV-VIS spectrophotometer after appropriate 
dilution. 
3.2.2 Physico-chemical characterization 
3.2.2.1 Differential scanning calorimetry (DSC) 
DSC is a thermo-analytical technique that measures the thermal transitions of a sample as a 
function of temperature against time [4].  DSC curves were recorded for TQ and TQ-NSPs 
using DSC (TA Instruments, USA). An accurately weighed (3.5 mg) amount of TQ and TQ-
77 
 
NSPs were placed in aluminium pan and then scanned in a temperature range from 25° to 
100°C with a heating rate of 5 °C/min.  
3.2.2.2 Fourier transform infrared spectroscopy (FTIR) 
The FTIR spectral measurements of thymoquinone and nanosuspension formulations were 
performed using a PerkinElmer-FTIR spectrometer, with a resolution of 4 cm-1, and 64 scans. 
Pure TQ and TQ nanosuspensions were mixed with the KBr to result in pellet and then 
examined for FTIR spectra with the scanning range of 400 to 4000 cm-1 (Frontier Optica, 
PERKIN ELMER). 
3.2.2.3 Colloidal Stability 
For the determination of short-term colloidal stability, TQ-NSPs were stored at 4°C for 24 h 
and change in particle size, and drug content was determined up to 24 h. 
3.2.2.4 Storage stability 
For long term stability, lyophilized TQ-NSP were stored at 4°C for a period of 2 months and 
change in particle size, and drug content was determined using UV-vis spectrophotometer 
3.2.3 Biological evaluation 
3.2.3.1 Cell culture 
MCF-7 cells were maintained in DMEM media, while PC-3, MDA-MB 231 and A549 cells 
were maintained in RPMI 1640 media. All cell lines were cultured in 10% FBS with 100 
units/mL penicillin and 100 µg/mL streptomycin. Cell lines were maintained at 37 °C with 5% 
CO2.  
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3.2.3.2 MTT assay 
Actively growing MCF-7, PC-3, MDA-MB 231 and A549 cells in their log phase of cell cycle 
were seeded into a 96 well plate at a concentration of 10,000 cells per well. Cells were treated 
with increasing concentrations of TQ or TQ NSPs ranging from 5, 10, 25, 50 and 100 µM for 
a period of 24, 48 or 72 h. The toxicity was assessed using the standard MTT assay, which 
analyses cellular viability by measuring the mitochondrial dehydrogenase activity due to 
reduction of yellow tetrazolium (MTT) to purple needle like formazan crystals. These crystals 
are solubilised in acidified isopropanol and measured by a UV-Vis multiwell plate reader at 
570 and 630 nm. 
3.2.3.3 Intracellular Reactive Oxygen Species (ROS) estimation 
MCF-7 cells were seeded at a density of 1 × 105 cells per mL and allowed to grow for a period 
of 24 h. The cells were then treated with 10 µM TQ or Dend-TQ (as per the IC50 values for 48 
h) for 24 h. ROS production was assessed using carboxy-H2DFFDA. This compound gets 
oxidized to a fluorescent product in the presences of ROS within the cells. After treatment, 
cells were fixed in 4% paraformaldehyde for 10 minutes, washed with PBS (at least twice) and 
5 µM of carboxy-H2DFFDA was added to the cells and incubated for 30 minutes in the dark at 
room temperature. The cells were washed thoroughly and the levels of ROS generation were 
observed using a Nikon fluorescent microscope (Nikon Eclipse TS100, Japan) with a 475-490 
nm excitation wavelength.          
3.2.3.4 Mitochondrial membrane potential (DΨM)  
DΨM was assessed using Rhodamine 123 after MCF-7 cells were treated with increasing 
concentrations of TQ and Dend-TQ for 24 h. About 1 × 105 cells were seeded in a 12 well plate 
and incubated at 37 °C overnight, in presence of 5% CO2. The cells were washed with warm 
PBS and treated for 30 minutes with 5 µg/mL of Rh123 after which the plate was observed 
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using a Nikon fluorescent microscope (Nikon Eclipse TS100, Japan) with a 475-490nm 
excitation wavelength. For quantitative analysis the cells were seeded at same concentration as 
above but after treatment, the cells were washed with PBS and trypsinized and collected in 1 
mL eppendorf tubes. The cells were then checked for fluorescence at excitation of 480 nm and 
emission at 490–700 nm. The graphs were plotted as a function of relative mean fluorescence 
intensities. 
3.2.3.5 Annexin V-Propidium iodide analysis 
The cells were analyzed for apoptosis by using the Annexin-V FITC and evaluation was done 
using flow cytometery. Briefly, MCF-7 cells were seeded in 6-well plate at the density of 1x 
106 cells per well and incubated overnight at 37 °C at 5% CO2. The cells were dislodged and 
washed twice with ice cold PBS. Finally the cells were resuspended in 1X Annexin binding 
buffer and incubated with 5 μL of Annexin -V FITC and 1 μL of propidium iodide (5 mg/mL) 
for 15 minutes in dark at room temperature. The cells were then analysed on the BDS Canto II 
flow cytometer by measuring fluorescence at 575 nm emission and 488 nm excitation. The data 
was analyzed with help of FlowJo software (Tree Star Inc., Ashland, US).  
3.3 Results and discussion 
3.3.1 Preparation and physicochemical characterization of TQ nanosuspensions  
Nanosuspension has emerged as an important technology in the development of the 
formulation of water insoluble drugs. It reduces the particle size of the solid drug below sub-
micron, typically 5-50 nm. This enhances the solubility of the drug/phytochemical [9]. The 
small size is responsible for reducing the rate of sedimentation of the particles and hence 
increases the physical stability. In this study, TQ-NSPs were synthesized and stabilized using 
TPGS by both bottom-up and top-down approaches.  
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In the precipitation method, TQ was dissolved in ethanol and dispersed in TPGS surfactant 
solution. The dispersion was required to control the process of nucleation and accelerate 
molecular diffusion. The organic solvent (ethanol) was then evaporated by magnetic stirring to 
precipitate the phytochemical in its nanoparticle form. The presence of TPGS in the aqueous 
phase inhibited the agglomeration of nanoparticles (TQ-NSP A).  
In homogenization approach, TQ was dissolved in chloroform and then emulsified in TPGS 
solution. The formed coarse emulsion was homogenized to form nano-emulsions. In this 
approach, the chloroform was evaporated by rotary evaporation to give nanosuspension of TQ 
in TPGS solution (TQ-NSP B).  
Both TQ-NSP A and TQ NSP-B, were evaluated for particle size, polydispersity index PDI 
and surface charge using Zetasizer Nano ZS (Malvern Instruments Ltd,  Malvern, UK) . The 
observed particles size for TQ-NSP A and TQ NSP-B was found to be 12.7±2.12 nm and 
11.2±2.2 nm, respectively (Figure 3.3). Zeta potential represents the surface charge of a 
nanoparticle which depends upon the chemical properties of the coating or dispersing agent. 
There was no significant difference in the zeta potential of both nanosuspension formulations. 
The observed zeta potential values for TQ-NSP A and TQ NSP-B were -15.8 and -16.3 mV, 
respectively. Since as dispersing agent, TPGS (0.25 % w/v) was used for the preparation of 
both nanosuspensions, a similar zeta potential is observed for both the suspensions.  The 
polydispersity index (PDI) of TQ-NSP A and TQ NSP-B was 0.271 and 0.195 respectively. 
The results revealed that TQ NSP-B had smaller particlesize along with lower PDI in 
comparison to TQ-NSP A.  
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Figure 3.3 Physicochemical characterization of the TQ Nanosuspensions (a) Size distribution 
of TQ-NSPA and B (b) FTIR spectra of TQ, TQ-NSPA and TQ-NSP B (c) DSC graph of TQ, 
TQ-NSPA and B 
In the Figure 3.3 (b) FTIR spectral studies of TQ and nanosuspension formulation of TQ were 
carried out to investigate the interaction between the functional groups of TQ with the 
nanosuspension. FTIR spectral analysis of TQ vibrational modes in its native form and its 
nanosuspension form provide insight into its structural integrity and retention of functional 
group in the nanosuspension form. Figure 3.3 (b) showed the FTIR spectra of TQ and its 
nanosuspension forms. Pure TQ showed a strong vibrational peak at 1637 cm-1, which 
(a) (b) 
(c) 
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corresponds to the –C=O group vibration. However, this carbonyl group was shifted to 1747 
cm-1, which may be probably due to confinement of nanoparticulate TQ within the suspension 
that restricts the keto-enol tautomerism. Moreover, the intense band at 2967 cm-1 corresponds 
to C-H stretching of aliphatic group, but this peak was shifted to 2925 cm-1 and a broad O-H 
stretching centered around 3400 cm-1. This was probably due to the interaction of aliphatic 
chains interaction with the hydrophobic interior of nanosuspension. Appearance of new O-H 
broad band in the nanosuspension was attributed to the hydrogen bonded interaction between 
the keto oxygen with the solvent hydrogens. From the FTIR analysis, it is clearly shown that 
TQ entrapped within the nanosuspension without any modification of TQ itself. The nature of 
interaction between TQ and nanosuspension are mainly the   hydrophobic and hydrogen bonded 
interaction, which was concluded from the shift in the vibrational frequencies correspond to 
the TQ functional groups. Therefore, TQ encapsulated within the nanosuspension is likely to 
retain its functionality, which is essential for the TQ nanosuspension to render the desired 
therapeutic action.  
The physical state of TQ in its native form and nanosuspension was determined by DSC [Figure 
3.3 (c)] TQ, TQ-NSP A and TQ-NSP B. The powder of pristine TQ showed a sharp melting 
endothermic peak at 46.5 °C, while no such melting was observed for TQ-NSP-A and TQ-
NSP-B. The results suggested that the crystalline form of native TQ was transformed to  
amorphous form during nanosuspension preparation.  
It is evident from the DLS data (p>0.05) how the size of the nanosuspension of TQ after storage 
as lyophilized powder (Figure 3.4). After storage as colloidal suspension, the size of the 
formulation was slightly increased after 24 h. The particle size changed from 12.7 ± 3.1 nm 
and 11.2 ± 2.2 nm at 0 day to 19.29 ± 1.8 nm and 16.4±2.6 nm within 24 h, respectively. After 
60 days the size of TQ-NSP A increased from 19.29±1.8 nm to 34.52 ± 5.7 and that of TQ-
NSP B increased from 26.8 ± 1.4 The observed drug content for TQ-NSP A and TQ-NSP B 
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was 98.7% and 99.4% after storage as colloidal suspension after 24 h when stored as 
lyophilized powder respectively. The results indicated that TQ-NSP A and TQ-NSP B are 
equally unstable during long term storage.    
 
Figure 3.4 The graphs represent the stability studies performed with TQ-NSP A and B. (a) 
colloidal stability (up to 24 hours) (b) storage stability (up to 60 days) 
3.3.2 Dose and time dependent cytotoxicity of TQ-NSP in breast cancer cell lines 
Two different types of human breast adenocarcinoma viz. MCF-7 and MDA-MB-231 were 
exposed to TQ, TQ-NSP A (homogenization) and TQ-NSP B (precipitation).  The cells were 
treated with increasing concentrations (5, 10, 25, 50 and 100 µM) of the TQ, TQ-NSP A and 
TQ-NSP B in a dose dependent manner for 3 different time points viz. 24, 48 and 72 hours.   
(Figure 3.5) 
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Figure 3.5 Comparison of cytotoxicity of TQ-NSPs in MCF-7 and MDA-MB-231 at three 
different time points (24, 48 and 72 h) produced by two different methods 
From Figure 3.5, TQ appears to be effective in both breast cancer cell lines. In MCF-7 cells 
there is a steady decline in the viability with increasing concentrations of pristine TQ at 24 h. 
The 48 h time point is similar at sub-toxic concentrations of TQ but slightly more effective at 
higher concentrations viz. 25, 50 and 100 µM. Another important observation included that the 
cells at 72 h showed recovery in MCF-7 (table 3.1). MDA-MB-231 cells also showed a similar 
trend to MCF-7 cells, where the viability decreases with increase in concentration of pristine 
TQ. However, MDA-MB-231 cells show higher sensitivity to TQ over MCF-7 cells.  
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Table 3.1: Comparison of IC50 values (µM) between TQ and TQ-NSP on two different breast 
cancer cell lines after 24, 48 and 72 h 
Samples Cell Lines 24 h 48 h 72 h 
TQ MCF-7 25.40 15.43 24.63 
MDA-MB-231 16.18 15.46 22.08 
TQ-NSP A MCF-7 21.59 16.56 12.28 
MDA-MB-231 14.24 7.14 8.01 
TQ-NSP 
 B 
MCF-7 15.57 13.72 7.81 
MDA-MB-231 8.33 7.23 1.23 
 
When MCF-7 cells were treated with TQ-NSP A, it did not show considerable effect at lower 
concentrations of TQ and the toxicity was similar to that of pristine TQ at 24 and 48 h. However 
at 72 h, TQ-NSP A showed a decline in the viability in contrast to the results of pristine TQ. 
This decline was similarly noticed in the case of TQ NSP B, though MCF-7 showed more 
sensitivity towards TQ-NSP A at 72 h. The results from the graph suggest that recovery of 
MCF-7 cells was subsided by both TQ-NSP formulations at 72 hours in comparison to pristine 
TQ.  
This improvement in the toxicity profile would possibly address the problems associated with 
TQ that are previously discussed in (Chapter 1 section 1.6). The stability of the compound 
plays a vital role in the effectiveness of the phytochemical [10-14].  
MDA-MB-231 showed higher sensitivity towards both TQ-NSP formulations. In case of TQ-
NSP A, The cells at lower TQ concentrations did not show much change in the viability. 
However, there was a sharp decrease in viability (below 20 %) observed at concentrations-25 
µM and above at each time point ( Figure 3.5) with less effect seen due to higher cell death at 
72 h time point.  
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In case of TQ-NSP B, results from graph showed similar effects at 72 h in MDA-MB-231 cells. 
Overall TQ-NSP B showed better improvement in the efficacy, in comparison to TQ-NSP A. 
The viability decreased to 20% at 10 µM upon treatment with TQ-NSP B in contrast to 20% 
viability at 50 µM in case of pristine TQ. 
In order, to increase the understanding on the cytotoxicity profiles of each TQ-NSP 
formulation, IC50 was calculated (Table 3.1) at each time point and cell line with various 
treatments viz. TQ, TQ-NSP A and TQ-NSP B. IC50 is a quantitative measurement that 
indicates the concentration of phytochemical showing 50% inhibition of cancer cells. This 
measurement helps to determine the efficacy of TQ or TQ-NSP in each cell line.  
With pristine TQ, it showed an initial decrease in the IC50 value when moving from 24 h to 48 
h in case of both lines. However, after 72 h treatment, IC50 values of both cell lines increase 
which a clear sign of recovery.  It also indicates that MDA-MB-231 is more sensitive to TQ 
compared to MCF-7 cells which is similar to some earlier studies by other investigators [15]. 
The reason behind better efficacy of TQ in MDA-MB-231 cells was suggested due to the 
morphology of cells. MCF-7 cells grow in colonies/clusters attached to each other unlike the 
MDA-MB-231 cells that grow and migrate individually presenting more surface area exposed 
to TQ [16].  The IC50 values from the Table 3.1 also indicated the decrease in IC50 value by 
2 times in MCF-7 cells and ~3 times in MDA-MB-231 cells during TQ-NSP A treatment (72 
h) in comparison to pristine TQ. In case of TQ-NSP-B treatment, the IC50 values showed 
decline by 3.15 times in MCF-7 cells and ~18 times in MDA-MB-231 over 72 h. These values 
suggest that MCF-7 to be a slightly more resistant to both nanosuspensions in comparison to 
MDA-MB-231.  TQ-NSP B’s toxicity is much better compared to TQ-NSP A. 
A possible reason to explain the effectiveness of nanosuspension is the size of nanosuspension 
of TQ compared to pristine TQ in aqueous form. Smaller size increases the ease of crossing 
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the phospholipid bilayer membrane of the cells. This provides higher biosorption and 
bioavailability at the target site [17, 18]. In 2015, Han et al. showed that the IC50 value in 
HepG2 cells (liver carcinoma) of Glaucocalyxin A (GLA) nanosuspension was lowered in 
contrast to the pristine GLA solution after 24 h incubation. The increase in the effectiveness 
was as result of either increase in the number of particles internalized into the cells via 
endocytosis or phagocytosis due to smaller size or by non-specific adsorption by pinocytosis 
after accumulation on the cells [19]. Another report on silybin nanosuspension prepared by 
high pressure homogenization method also showed changes in morphology of PC-3 cells along 
with increase in formation of apoptotic bodies and increased cell death due to increase in 
efficacy in contrast to the pristine silybin solution [20]. One of the reports suggested that 
honokiol, a phytochemical when converted to nanosuspension form, it was found to improve 
the oral bioavailability along with alteration in the bioavailability during intraperitoneal 
administration with increase in levels in blood, heart and brain [21].  
The overall results suggest that reduction in the size of TQ to nano-particulate form increases 
the cytotoxicity at 10 µM TQ concentration improving its therapeutic efficacy compared to 
pristine TQ.  
From the table 3.1 above, a distinct difference is seen in the IC50 values with respect to MDA-
MB-231 cells when treated with TQ-NSP A & B. However, TQ-NSP B shows higher efficacy 
(by 7 times) and higher sensitivity towards MDA-MB-231 compared to TQ-NSP A (Table 3.1). 
This is evident from reduction in IC50. Hence, TQ-NSP B was chosen for further studies in 
MCF-7 and MDA-MB-231 cells. 
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3.3.3 Intracellular ROS generation 
The MTT assay results helped to assess the change in toxicity profile upon decreasing the size 
of TQ. Out of both NSP formulations, TQ-NSP B showed better improvement in toxicity 
profile on both cell lines and showed higher anti-proliferative effect on MDA-MB-231. 
Therefore, MDA-MB-231 was also included for all further studies along with MCF-7 cells. As 
mentioned earlier, aim of this chapter was to improve the stability and therapeutic efficacy of 
TQ. Hence, a 10 µM dose was chosen as the optimal concentration of TQ for performing all in 
vitro assays. The cells were treated with pristine TQ and TQ-NSP B. The cells were stained 
with carboxy-H2DFFDA; a dye that is cell membrane permeable. It is deacetylated with help 
of cellular esterases within the cells which leads to formation of non-fluorescent compound, 
which upon reacting with ROS get oxidised giving a fluorescent signal. The amount of ROS 
generation increased in the cells in the following order:  
Untreated cells< TQ < TQ-NSP B 
 
Figure 3.6 Confocal micrographs of fixed cells treated with carboxy-DCFFDA to observe the 
ROS generation at different treatments in MCF-7 and MDA-MB-231 viz. control, pristine TQ 
and TQ-NSP B (Scale bar: 50 μm) 
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The results shown in the Figure 3.6 suggest an increase in ROS generation by TQ and TQ-NSP 
B. However, there was an elevation in the levels of ROS generated TQ-NSP B compared to 
pristine TQ. These results were further proven with the help of quantitative analysis using a 
fluorescence spectrophotometer presented below in Figure 3.7. The fluorescence intensities 
obtained from all three samples were normalized against the untreated cells and plotted as 
function of change in ROS generation. The quantitative results from the fluorescence 
measurement study are in agreement with the Figure 3.6. According to the graph in the Figure 
3.7, over untreated there is a 0.75 and 1.25 fold increase in ROS activity in MCF-7 cells and 
MDA-MB-231, respectively while using TQ-NSPB. These results indicate that MDA-MB-231 
cells are more sensitive to TQ-NSP B when compared to MCF-7 cells, which was also observed 
in terms of toxicity.  
 
Figure 3.7 The graph represents fluorescence intensities obtained from all three samples 
normalized against the untreated cells and plotted as relative reactive oxygen species 
generate. The data was presented as mean ± standard error (SE) of three independent 
experiments. 
According to Zubair et al, TQ can switch between pro and anti-oxidant activity in presence of 
low concentration of metal ions [22]. They showed TQ could possibly interact with cellular 
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copper in cancer cells and lead to cytotoxicity by pro-oxidant mechanism. Another study in 
2013, reported increase in DNA damage due to increase in ROS activity in chondrocytes 
(primary cell line) in a dose dependent manner in support of this finding [23]. 
 As mentioned in published reports, TQ is well known as pro and anti-oxidant in cancer cells 
[22-26]. As a pro-oxidant, it was observed that TQ increases ROS levels, which is involved in 
a variety of biological functions that include mutation, inflammation, aging, development, 
carcinogenesis and many other diseases. These superoxide radicals, hydrogen peroxide, singlet 
oxygen and hydrogen radicals as a result of various metabolic processes are known to be fatal 
to healthy as well as cancerous cells. Chronic increase in the ROS production can lead to 
accumulation of ROS associated cellular damages affecting protein lipids and DNA [27, 28].In 
general, cancer cells are resistant to higher levels of ROS compared to healthy cells, but there 
is fine balance, which if disturbed leads to cell death via apoptosis. Excess ROS generated is 
harmful to cells and usually connected with changes or disruption of mitochondrial membrane 
too. Hence, it was necessary to probe the effect of ROS in relation to the change in the 
mitochondrial membrane potential. 
3.3.4 Mitochondrial Membrane potential (DΨM) 
The change in the DΨM was assessed in MCF-7 cells and MDA-MB-231 in presence of TQ 
and TQ-NSP B. After the 24 hour incubation the cells were washed and treated with Rh123. 
Since Rh123 is a cell-permeant, cationic, fluorescent dye; it is readily sequestered by active 
and intact mitochondria without inducing cytotoxic effects. Intact mitochondria have relatively 
high negative electric potential across the mitochondrial membrane which in turnallows 
accumulation of cationic Rh123 molecules within it [29-31]. However, change in membrane 
potential leads to membrane depolarization which leads to low uptake of Rh123; hence less 
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fluorescence intensity is observed. The fluorescence micrographs in the Figure 3.8 were used 
for qualitative analysis. 
 
Figure 3.8 Confocal micrographs of live cells treated with Rhodamine123 to observe the 
change in DΨM at different treatments in MCF-7 and MDA MB-231: Control, Pristine TQ 
and TQ-NSP B (d) (Scale bar: 50 μm) 
The qualitative results suggested a steady decline in the intensities in confocal micrographs in 
Figure 3.8, which was in agreement with quantitative measurement of mean fluorescent 
intensities. The Figure 3.9 depicts MCF-7 cells, upon pristine TQ treatment which showed the 
decrease of ~ 0.3 fold in DΨM with regards to untreated. This effect is retained in the case of 
TQ-NSP B which is slightly higher than 0.6 foldswhen compared to untreated cells.  
DΨM is the charge on the mitochondrial membrane which allows it to remain intact in the 
cytoplasm. The decrease in the charge intensities suggests that there is a change in DΨM which 
could be responsible for a leaky organelle. Mitochondria are considered as the main source of 
reactive oxygen species (ROS). When disruption of the mitochondrial membrane occurs due 
to change in the membrane potential, it allows the release of catabolic activators that exert 
pressure on both vital and lethal cellular functions, simultaneously in both viz. physiological 
and pathological pathways. The termination of mitochondria’s biological redox function occurs 
with release of catabolic enzymes that lead to cellular destruction [23, 31, 32]. Catabolic 
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enzymes play a pivotal role in initiating apoptosis by causing DNA damage along with 
destruction of mitochondrial stability (which is a powerhouse of the cell) [32-34]. Hence, it is 
also prescribed as “a point of no return” since the programmed cell death is initiated at this 
stage. The above results suggest that since TQ-NSP B caused a significant shift in the 
membrane potential, the likelihood of apoptosis would also increase. Hence, it was essential to 
determine the occurrence of apoptosis in both cell lines due to TQ-NSP B in comparison to 
pristine TQ.  
 
Figure.3.9 The graph represents fluorescence intensities obtained from all three samples 
normalized against the untreated cells and plotted as function of change in DΨM. The data 
was presented as mean ± standard error (SE) of three independent experiments. 
3.3.5 Apoptosis 
With the increase in mitochondrial membrane permeabilisation, a critical threshold in cancer 
cells is surpassed, which leads to rapid cell death via a variety of independent and redundant 
mechanism [30, 34].    
The process of maintenance and renewal of cells to main homeostasis in normal functioning of 
cells is vastly governed by the phenomena known to us as apoptosis. The disruption caused 
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within genetically defined programmed cell death would be a major cause for endless 
proliferation of cancerous cells. In order to understand the effect of change in levels of ROS 
and membrane potential of mitochondria, cells were checked for apoptosis using Annexin 
V/FITC-PI staining assay [35-40].  When apoptosis is initiated, phosphatidyl serine residues 
appear on extracellular part of cell membrane which is a hallmark of apoptosis. FITC tagged 
Annexin V is known to bind these phosphatidyl serine residues and its fluorescence is measured 
using flow cytometery. PI is used in conjunction with Annexin V to determine the damaged 
and dead cells in the population.  
 
Figure 3.10 The flow analysis of Annexin-V FITC Assay for determination of apoptosis in 
MCF-7 and MDA-MB-231 with TQ and TQ-NSP B treatment for 24 h 
The flow cytometery results from (Figure 3.10) indicated that TQ-NSP B at 10 µM TQ 
concentration induced apoptosis at higher levels compared to TQ. After 24 hour treatment, 
Annexin positive cells increased 24.9 % in TQ to 48.2% in MCF-7 cells and 24.9 % to 55 % 
rise in MDA-MB-231 cells due to TQ-NSP B treatment suggesting a rise in early apoptotic 
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phase. The graphical representation (Figure 3.11) for the apoptotic cells below suggests that 
there is a distinct rise in the apoptotic cells with respect to TQ-NSP B.  
A similar formulation study involving oridonin (extracted from Rabdosia rubescens) suggested 
that the nanosuspension formulation not only enhanced the toxicity in a time dependent manner 
but also showed improvement in the ratio of early apoptotic cells [41]. Zheng et al. in 2011 
also showed similar results which included increase in the apoptotic bodies with rise in the 
ratio of apoptotic cells upon silybin nanosuspension [20].  
 
Figure 3.11 Graphical representation comparing the ratio of apoptotic cells of TQ and  
TQ-NSP B in MCF-7 and MDA-MB-231 
3.4 Conclusion 
In summary, nanosuspensions of TQ with help of a surfactant TPGS were prepared using two 
different methods viz. precipitation (TQ-NSP A) and homogenization (TQ-NSP B). 
Nanosuspension method was used to increase the solubility and stability of TQ in the solution. 
Upon characterization, both the methods resulted with DLS sizes and zeta potential within 
similar range. However, the polydispersity index of TQ-NSP-B was lower than TQ-NSP A. 
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This effect might have potentially translated to the cytotoxicity profile of both breast cancer 
cells lines. The MTT assay conducted on the breast cancer lines showed a decline in the 
viability for both TQ-NSPs. However, TQ-NSP-B showed improvement in efficacy in 
comparison to the TQ-NSP A. Upon further investigation results revealed that TQ-NSP B had 
increased range of apoptotic cells through increased generation of ROS and damage to the 
mitochondrial membrane leading to increased cell death.  
Overall results from the above study suggest that nano-formulation of TQ can be an alternative 
for the improvement in stability and therapeutic efficacy of TQ. 
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Chapter 4: Thymoquinone encapsulation in dendrimers enhances 
its efficacy towards breast cancer  
4.1 Introduction 
Thymoquinone (TQ) has shown promising anti-cancer activity against various cancers such as 
breast, lung, prostate, liver and colon cancers, [1-5]. This effect of TQ is shown to be due to its 
antioxidant, anti-inflammatory, anti-neoplastic, anti-metastasis and anti-angiogenesis 
properties [2, 3, 6-9]. Thymoquinone has the ability to induce apoptosis and inhibit tumour cell 
growth in vitro and in vivo model such as mice [4, 5, 10-13]. Due to its broad spectrum of 
antioxidant potential, it is associated with the ability to alter “redox state” and scavenge free 
radicals, generating reactive oxygen species (ROS) through variation of antioxidant enzymes 
such as superoxide dismutase, glutathione peroxidase and catalase. 
However, from the previous chapter, it was observed that TQ at sub-toxic concentration can 
lead to triggering of Epithelial to mesenchymal transition (EMT) making cancer more 
aggressive or immune to TQ. Clinical and therapeutic applications of TQ are limited due to its 
poor aqueous solubility and high physico-chemical instability. TQ is highly sensitive towards 
light, pH and temperature changes [9, 12, 14].   
The therapeutic efficacy of any drug/ phytochemical is most often reduced due to its 
incapability to gain access to the site of action due to its insolubility in aqueous environment. 
Advances in nanotechnology provide an insight into various drug delivery vehicles to increase 
the longevity of the drug as well as reduces the dosage to achieve effective therapy. Dendrimer 
is one such nanocarrier that is branched, synthetic polymers with layered architecture that show 
promise in several biomedical applications. Dendrimers are monodisperse, macromolecular, 
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globular polymeric architecture having several unique advantages over conventional drug 
delivery system [15].  
The dendrimers possess some unique properties, such as uniform size, water solubility, high 
degree of branching, high surface area for adsorption, multi-valency, well defined molecular 
weight and available internal cavities, which make it a suitable candidate for drug delivery 
applications. This provides an enormous surface area in relation to volume. Its globular shape 
and internal cavities provide possibility to encapsulate guest molecules within the 
macromolecular interior.   
With well-defined nano-size structural design and the internal cavities dendrimers have the 
ability to carry the water insoluble drugs in its internal cavities that help to cross biological 
barriers, to increase the blood circulation time of drugs needed to exert a clinical effect, and to 
enhance the stability of drug molecules [15, 16]. Another important attribute of dendrimers is 
its biodegradability, which prevents its bioaccumulation of possible toxic effects in the body. 
Polyamidoamine (PAMAM) dendrimers are the most studied that hydrolytically degrade due 
to presence of amide backbone at physiological temperatures [17, 18]. Dendrimers also contain 
thiol-reactive disulfides within their branches that can be cleaved under the reducing conditions 
encountered within the cells. Moreover, the dendrimers functions itself as an enzyme substrate, 
which leads to possibility for its degradation by enzymes in the cell [15, 18, 19].  
The first dendrimer family to be completely synthesized and characterized (in 1984) was poly 
(amido amine) dendrimers, also known as PAMAM dendrimers. Divergent method is used to 
synthesize dendrimers. This involves a two-step iterative reaction sequence that generates 
concentric shells of branches around the initiator core. The core shell architecture grows 
linearly in diameter, while the surface groups grow exponentially. Due to this growth, causing 
102 
 
congestion between core and branch cell diversities to produce geometrically closed nano 
structures that exhibit hydrophobic host-guest cavities [20].  
The rationale behind using dendrimers: 
 The process of biodistribution and its pharmacokinetic properties can be controlled by fine 
tuning the size and conformation of the dendrimer.  
 Dendrimers maintain high structural and chemical homogeneity due to which there is less 
batch to batch variations in production as well as its facilitates the reproducibility of 
pharmacokinetic data within different batches.  
 They have the ability to be functionalised or conjugate with various drugs, chromophores 
ligands or phytochemicals either on their surface or within their hydrophobic cavities. 
They help to increase the drug payload by attaching to other carriers such as biocompatible 
polymers or antibodies.    
 Dendrimers are biocompatible and biodegradable in an in vivo system. These 
characteristics can be attained by careful choice of the available dendrimer chemistry.  
In this study, a PAMAM dendrimer formulation is demonstrated to encapsulate TQ in order to 
improve its solubility in aqueous media and improve its stability and cytotoxicity by protecting 
within the internal cavities of the dendrimer. The TQ loaded dendrimers were characterised for 
particle size, encapsulation efficiency, in vitro release and improvement of anticancer activity 
against different cancer cells was tested. 
4.2 Materials and methods 
4.2.1 Chemicals and Materials 
G4 amine-terminated PAMAM dendrimers with diaminobutane core were purchased from 
NanoSynthons LLC (Mt Pleasant, US). TQ was purchased from Sigma Aldrich (St. Louis, US). 
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MCF-7 human breast cancer, PC3 human prostate cancer cells, MDA-MB-231 human breast 
cancer cells and A549 human lung cancer cells were purchased from American Type Cell 
Culture (Rockville, USA). Roswell Park Memorial Institute (RPMI) 1640 media, Dulbecco's 
modified eagle medium (DMEM), penicillin-streptomycin 10,000U/mL, trypsin-EDTA 
(0.25%), (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (MTT), phosphate 
buffered saline pH 7.4 (PBS), carboxy-H2DCFDA, rhodamine 123 (Rh123) , Dead cell 
apoptosis kit with Annexin V FITC was purchased from Life Technologies Pty Ltd . Foetal 
Bovine Serum (FBS) was purchased from Interpath Services Pty Ltd. Paraformaldehyde was 
purchased from Electron Microscopy Sciences (Hatfield, US) and brought to 4% in PBS and 
chilled to 4°C right before use.  
4.2.2 Preparation of dendrimers-TQ complexes 
Dendrimer-TQ (Dend-TQ) complexes were prepared by solvent casting method. Dendrimers 
(0.2 and 0.4% w/v) and TQ were dissolved in methanol and then Dend-TQ complexes were 
extracted in PBS for 24 h. Dend-TQ complexes were kept overnight for equilibrium between 
dendrimers and TQ molecules. The aqueous solution were filtered through 0.2 µm syringe filter 
and stored at 4 °C. TQ concentration in each dendrimer formulation was determined at 260 nm 
absorbance wavelength using UV-vis spectrophotometer (Agilent Technologies, Melbourne, 
Australia).  
4.2.3 Physico-chemical characterization of Dendrimer-TQ complexes 
TQ and Dend-TQ were dissolved in PBS and scanned in the wavelength-range of 200-800 nm 
using UV/vis spectrophotometer. For Fourier Transmission Infra-Red (FTIR) spectrum 
analysis, dendrimers, TQ and lyophilized Dend-TQ complexes were scanned for transmittance 
against wave number 650-4000 cm-1 using a FTIR system (Perkin Elmer, US). For 1H NMR 
analysis, dendrimers, TQ and Dend-TQ were dissolved in either D2O or D6-dimethyl sulfoxide 
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and analysed using Nuclear Magnetic Resonance - Bruker Avance 300 MHz from Bruker Pty 
Ltd (Melbourne, Australia). 
4.2.3.1 Determination of hydrodynamic radius and zeta potential  
The mean particle size and zeta potential of different formulations were determined by dynamic 
light scattering (DLS) technique using Zetasizer Nano ZS (Malvern Instruments, Malvern, 
UK). 
4.2.4 In vitro drug release studies 
In vitro drug release from Dend-TQ complex and TQ solution formulation was evaluated from 
the diffusion of the drug from the formulation kept within the dialysis bags [16, 17]. Dend-TQ 
complex or TQ solution, containing TQ equivalent to 2.5 mg, were placed in a dialysis bag 
(Cellophane membrane, molecular cut off 2000 Da). After that, the dialysis bag was immersed 
in 100 mL of PBS in a beaker. The system was maintained at 37 ± 0.5 °C under 100 rpm speed. 
At predetermined time intervals, 5 mL of aliquot was collected and the same amount of fresh 
medium was replaced to maintain the sink condition. The collected aliquots were filtered, 
diluted appropriately and analysed for the absorbance at 260 nm using a UV-vis 
spectrophotometer. 
4.2.5 Stability studies 
Thymoquinone was shown to degrade in the solution, therefore the stability of TQ in Dend-TQ 
complex and in solution was estimated. Dend-TQ complexes and TQ solution were stored at 
room temperature in dark and evaluated for drug content. For the accelerated stability, samples 
were stored at room temperature (25 ± 2 °C) in light and measured the absorbance at 260 nm 
at different time intervals up to three days using a UV-vis spectrophotometer.  
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4.2.6 Biological characterisation 
The methods used for biological characterisation are described in Chapter 3, section 3.2.3.  
4.3 Results and discussion 
4.3.1 Preparation of Dend-TQ complexes 
Dend-TQ complexes can be prepared by either dispersing an excess of solid 
drug/phytochemical in aqueous solution of dendrimers or by solvent casting method [21]. In 
solvent casting method, drug and dendrimers are dissolved in a common, evaporating solvent 
and then dendrimer-drug complexes in aqueous phase.  Deep et al. observed that hydrophobic 
drugs such as docetaxel and paclitaxel were encapsulated more by solvent casting method than 
dispersion method [21]. Therefore, in this study Dend-TQ complexes using solvent casting 
method were prepared. The absorbance-concentration curve was rectilinear in the 
concentration range 0.05-5 µg/mL with regression equation y=0.1895x-0.0002 and regression 
coefficient r2 = 0.9997.  
The results of TQ encapsulation in different dendrimer formulations are shown in Figure 4.1. 
The TQ concentration was found to be 741.9 and 1332 µg/mL with 0.2% and 0.4% w/v G4-
NH2 PAMAM dendrimers, respectively. The results clearly indicated that the solubility of TQ 
was increased with increasing dendrimer concentration. PAMAM dendrimers have been well 
reported as solubility enhancer for hydrophobic drugs [17]. The enhanced solubility of TQ 
could be explained by host-guest interaction between dendrimers and TQ. The interior cavities 
of dendrimers have hydrophobic environment which encapsulate water-insoluble drugs. The 
encapsulation of TQ in these cavities could be a reason for the enhanced solubility of TQ in 
Dend-TQ complexes.  
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Figure 4.1 Drug loading in PAMAM dendrimers viz. G4 (4th generation dendrimer) with an 
amine tail 
Apart from concentration of dendrimers, dendrimer-mediated solubility enhancement also 
depends on change of pH and surface groups present on dendrimers [16, 17]. Salmani et al 
reported that TQ is unstable at both acidic and basic pH. Therefore, Dend-TQ complexes were 
prepared at pH 7.4 [22]. Since 0.4% w/v G4-NH2 PAMAM dendrimers showed the highest 
amount of drug loading, it was chosen for further in vitro studies to determine the improvement 
in stability and therapeutic efficacy.  
4.3.2 Physico-chemical characterization of Dend-TQ complexes 
In order to investigate the nature of interaction between TQ and Dend, Dend-TQ complexes 
were characterized by UV-vis spectroscopy, FTIR and NMR analysis. Figure 4.2 (A) shows 
the UV/VIS spectra of TQ and Dend-TQ. Both plain TQ and Dend-TQ showed characteristic 
absorption band of TQ at 260 nm. There was no shift in the absorption band of TQ in Dend-
TQ indicating that TQ was encapsulated by simple host-guest interaction [15].  
107 
 
DLS was used to calculate the hydrodynamic radius of Dend-TQ complex. The average particle 
diameter estimated from DLS analysis Dend-TQ was 15.9+1.7 nm [Figure 4.2 (B)] and zeta 
potential 14.1+0.9 mV. 
 
Figure 4.2 Physicochemical characterization of the TQ loaded dendrimers (A) UV/VIS - 
spectra of TQ and G4 PAMAM Dend-TQ (B) Size distribution of Dend-TQ complex (C) FTIR 
spectra of G4 PAMAM dendrimers (G4 Dend), TQ and Dend-TQ (D) NMR spectra of TQ, 
Dendrimer and Dend-TQ 
To confirm the interaction between dendrimers and TQ, an FTIR study was performed ( Figure 
4.2 C). The FTIR spectra of TQ showed bands at 2967 cm-1 (C-H stretching of aliphatic group), 
1642 cm-1 (C=O vibration) and (C=C vibration). Two methyl groups of the isopropyl group 
showed doublet peaks at 1355 cm-1 and 1376 cm-1. Dendrimer’s FTIR spectra showed bands at 
3276 (N-H stretching), amide (1632 cm-1 and 1543 cm-1) and 1033 cm-1 (C-N stretching) [17]. 
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With an insignificant shift, Dend-TQ complex exhibited all the characteristic peaks of TQ at 
2964 cm-1, 1376 cm-1 and 1355 cm-1, indicating an electrostatic interaction between dendrimers 
and TQ. 
Further, NMR analysis also suggested successful complex formation between dendrimers and 
TQ (Figure. 4.2 D). The peak assignments in the 1H NMR spectra of TQ were as follows: 1.12 
(6H of two methyl groups of isoproyl side chain), 2.08 (3H of methyl side chain), 3.1 (1H 
of CH group of isoproyl side chain) and 6.4 and 6.6 for aromatic protons. The NMR spectra 
of lyophilized Dend-TQ exhibited peaks of TQ without significant shift, suggesting the lack of 
chemical interaction between TQ and dendrimers. Similar reports with regards to host-guest 
interaction have been reported in case of other phytochemicals/drugs [15, 16, 18, 19, 21, 23].  
4.3.3 In vitro drug release   
The release of TQ from Dend-TQ complex was investigated in PBS and compared with the 
release from TQ solution in DMSO (Figure 4.3). The TQ dissolved in DMSO exhibited a 
complete release and degradation in PBS within 4 h. However the release kinetics of Dend-TQ 
displayed about 81% release of TQ in 12 h. The slow release of TQ from Dend-TQ formulation 
could be attributed to encapsulation of TQ in interior cavities of dendrimers which act as 
hydrophobic pockets for storage. Hydrophobic interactions between interior cavities of 
PAMAM-NH2 dendrimers and hydrophobic drugs are mainly responsible for slow and 
sustained  release of TQ molecules from PAMAM dendrimers (as mentioned above) [17]. 
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Figure 4.3 In silico release of TQ from TQ solution and G4 PAMAM dendrimer-TQ complex 
(Dend-TQ) at 37 °C in PBS up to 24 h  
4.3.4 Stability studies 
Stability of TQ in the solution is a major concern in realizing its therapeutic efficacy. Figure 
4.4 shows the degradation behaviour of pure TQ and Dend-TQ. TQ concentration was rapidly 
declined in TQ solution in comparison to Dend-TQ complex. After 24 h, the stability rate 
constant was observed to be 3.9 × 10-3 and 12.6 × 10-3 for TQ in solution form and for TQ 
encapsulated in dendrimers. The linear regression line helps to determine the stability constant 
for each of the formulations. Higher the degradation constant indicates higher degradation rate 
of TQ in the formulation. The results demonstrate that TQ by itself in DMSO degrades faster 
than being encapsulated in the dendrimer based formulation.   
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Figure 4.4 In silico stability measured for TQ in solution and Dend-TQ stored at room 
temperature (25 ± 2 °C) 
4.3.5 Biological evaluation 
4.3.5.1 Determination of dose dependent cytotoxicity of Dend-TQ complex in array of 
cancer cell lines 
Four different cancer cell lines namely, A549 human lung cancer, PC-3 human prostate cancer 
and human breast adenocarcinoma (MCF-7 and MDA-MB-231) were exposed to pristine TQ 
and Dend-TQ complex to observe the effect of TQ. The cells were treated with increasing 
concentrations of pristine TQ or Dend-TQ complex for 24 hours.  
The ability of TQ and Dend-TQ to inhibit the proliferation of different cancer cell lines was 
determined by MTT Assay (Figure 4.5). In case of pristine TQ treatment, the breast cancer 
cells showed much higher sensitivity compared to lung carcinoma and prostate cancer cells 
after 24 h. MDA-MB-231 was most sensitive to TQ amongst all the cell lines and lung 
carcinoma cells almost remained unaffected even at high concentrations. Higher concentrations 
of TQ such as 25-50 μM showed most effect in all cell lines except lung carcinoma. At sub-
toxic concentrations of TQ in PC-3 the cells exhibited proliferation. This is an indication of 
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hormesis within 24 h. Hormesis is a phenomenon of dose- response relationship in which a  
toxic substance at low or sub-toxic concentrations depicts beneficial effects towards cancer 
cells and allows its proliferation [24]. 
. 
Figure 4.5 The graph shows cytotoxicity profile of TQ and Dend-TQ at different concentrations 
after 24 h exposure, in four different cancer cell lines viz. human breast adenocarcinoma 
(MCF-7 and MDA-MB-231), lung carcinoma (A549) and human prostate cancer cells (PC-3).  
Data are mean ± Standard error from three independent experiments 
Furthermore, this trend was also reported by Koka et al. (2010), in case of prostate cancer cells 
where there was increase in the cell viability at lower concentrations of TQ treatments [6]. The 
IC50 after 24 h was recorded to be 25.4 μM and 16.18 μM for pristine TQ in MCF-7 and MDA-
MB-231 cells respectively. However, in case of dendrimer formulation the IC50 was reduced 
to 7.61 μM and 3.68 μM in MCF-7 and MDA-MB-231 after 24 h treatment. The hormesis 
effect seemed to disappear from the PC-3 cells and even lung carcinoma cells showed a steady 
decline in cell viability at low or sub-toxic concentration. According to Darkashan et al. (2011), 
TQ was able to supress the growth of three independent breast cancer cell lines viz. MCF-7, 
MDA-MB-231 and BT-474 [40]. The results were similar to various studies performed in vitro 
and in vivo that indicated thymoquinone was cytotoxic and prevent carcinogenesis, and inhibit 
tumorigenesis through different molecular mechanisms [11, 25-35] The reason behind increase 
in the therapeutic efficacy of the TQ could be due to increase in the stability of TQ within the 
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dendrimer pockets and slow sustained release up to 24 h. Another factor involved would be 
efficient delivery of dendrimers into the cells. Dendrimers are small in size. Kannan and 
coworkers studied the dynamics of cellular uptake of PAMAM dendrimers (G4-NH2, G3-NH2, 
G4-OH, PEGylated G3 (G3-PEG)) into the A549 human lung epithelial carcinoma cells which 
showed that G4-NH2 and G4-OH entered into the cells more rapidly than did G3-NH2 or G3-
PEG [36]. The rapid entry of G4-NH2 dendrimer was a results of the cationic nature of the 
amine surface groups, which may interact electrostatically with negatively charged epithelial 
cells and enter via fluid phase pinocytosis. Usually the nanoparticles used as drug delivery 
carriers find the most difficult to cross the Blood brain barrier (BBB). However, Lee et al., 
were able to demonstrate the cellular internalization of G4- PAMAM dendrimers in to the 
primary neuronal cultures and central nervous system in vivo [20]. 
4.3.5.2 Intracellular reactive oxygen species (ROS) generation 
The cells were treated with TQ and Dend-TQ at concentration of 10 µM so as to compare the 
effect of TQ encapsulated within the dendrimer. The carboxy-H2DFFDA dye was used after 
fixing the cell in paraformaldehyde to preserve the activity within them. After diffusion into 
the cell, carboxy-H2DFFDA is deacetylated by cellular esterases within the cells to a non-
fluorescent compound, which is later oxidized by ROS [37]. This oxidation is responsible for 
the fluorescence and helps us to determine the increase or decrease in ROS generated within 
the cell.  
The results from the confocal micrographs in Figure 4.6 show decrease in fluorescence with 
both TQ and Dend-TQ. The amount of ROS generated was found to be higher in case of Dend-
TQ treatment in comparison to TQ treated cells. This result was further confirmed by 
quantitative analysis using a fluorescence spectrophotometer in Figure 4.6. The fluorescence 
intensities obtained from all three samples were normalized against the untreated cells and 
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plotted as function of change in ROS generation. The results were in agreement with those 
obtained from the fluorescent images. Similar results have been reported in case of the other 
cell lines viz. ovarian and colon cancer cell lines. Taha et al., (2016) reported the increase the 
cellular oxidative stress in the Caov-3 cells. Another study associated with the increase in ROS 
activity with increasing amounts of TQ was reported in the malignant T- cells. The amount of 
ROS generation increased in the cells in the following order:  
Untreated cells< TQ < Dend-TQ 
 
Figure 4.6 Confocal micrographs of fixed cells treated with carboxy-DCFFDA to observe the 
amount of ROS generated at different treatments in MCF-7 and MDA MB-231: Control, 
Pristine TQ and Dend-TQ (scale bar: 50 μm) 
 Figure 4.7 suggested that there was increase in the ROS generation with respect to TQ and 
Dend-TQ in both breast cancer cells lines. However, in case of MCF-7 cells there is relatively 
less ROS generation in comparison to TQ. A much better response was observed in MDA-MB-
231 cells, with respect to both cell lines in both treatments viz. untreated and pristine TQ. These 
results indicated a higher sensitivity of Dend-TQ in MDA-MB-231 cells rather than MCF-7 
cells.    
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Figure 4.7 The graph represents fluorescence intensities obtained from two samples viz. 
pristine TQ and Dend-TQ normalized against the untreated cells and plotted as function of 
change in ROS generation. Live cells were treated with Rhodamine123 to observe the change 
in DΨM in different treatments:  Untreated, pristine TQ, Dend-TQ. Data are mean ± 
Standard error from three independent experiments 
Uncontrolled ROS generation is injurious to the cells, since it can cause damage to DNA and 
other organelles in the cells leading to cell death [38, 39]. TQ has been reported for both anti 
and pro-oxidant activity [30, 40]. Since cancer cells already have higher levels of ROS, there 
is a very delicate and highly sensitive balance of ROS species generated in these cells. Hence, 
any disruption to this delicate ROS balance could lead to apoptosis. Indeed, there was a 
significant increase in ROS generation with Dend-TQ observed in both cell lines viz. MCF-7 
and MDA-MB-231. This study not only help us to understand the DNA damage occurring due 
to oxidative stress but also depicts the increase in the therapeutic efficacy of TQ with decrease 
in the phytochemical payload at low/sub-toxic concentration of TQ. With increase in the 
efficacy it also solves the issue involving the occurrence of EMT as noticed in the previous 
chapter (Chapter 2).  
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The increase in ROS level abnormally is known to disturb the equilibrium required in order to 
maintain the mitochondrial membrane potential (DΨM). Hence, it was an essential step to 
investigate the change in the DΨM in the cells as trace the effect of TQ and Dend-TQ. 
4.3.5.3 Mitochondrial Membrane Potential (DΨM) 
The change in ROS levels in the cell is also associated with change in the membrane potential. 
Rh123 is a cell-permeant, cationic, fluorescent dye that is readily sequestered by active 
mitochondria without inducing cytotoxic effects [41, 42]. In unaffected conditions, 
mitochondria is able to retain Rh123 giving a strong green fluorescent signal unlike the 
damaged or permeabilised state [42-45].  
In order to assess the change in DΨM, the MCF-7 and MDA-MB-231 cells were treated with 
TQ, Dend-TQ. After the 24 h incubation, the cells were washed and treated with Rhodamine 
123 (Rh123) checked for fluorescence for both qualitative and quantitative analysis. Results 
from the Figure.4.8 suggested steady decline in the fluorescence intensity in the confocal 
micrographs of both cell lines with treatment of TQ and Dend-TQ. However, there is a 
significant loss of fluorescence in the sample containing Dend-TQ in comparison to pristine 
TQ sample at the same concentration.  
A similar pattern was observed in the graph (Figure 4.9) when plotted as a function of change 
in mitochondrial membrane potential (DΨM) when compared to untreated cells. These 
observations clearly suggested increase in efficacy due to encapsulation of TQ within the 
PAMAM dendrimers, making it an attractive drug delivery model without changing the mode 
of action of TQ. Some studies upon extensive investigation suggested that increase in ROS 
activity and rupturing of the mitochondrial membrane could lead release of factors/ molecules 
that can lead DNA damage or breakage as well as activation different cascades leading to 
programmed cell death/ apoptosis [43, 45]. The cross talk between ROS and DΨM plays a vital 
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role in triggering the activation of apoptosis [42, 46]. Hence, TQ acts as a pro-oxidant in the 
above studies leading destruction and damage of breast cancer cell lines.    
 
Figure 4.8 Confocal micrographs of live cells treated with Rhodamine123 to observe the 
change in DΨM at different treatments in MCF-7 and MDA MB-231: Control, Pristine TQ 
and Dend-TQ (Scale bar: 50 μm)  
 
 
Figure 4.9 The graph represents fluorescence intensities obtained from two different samples 
treated with TQ and Dend-TQ normalized against the untreated cells and plotted as function 
of change in DΨM. Data are mean ± Standard error from three independent experiments 
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4.3.5.4 Apoptosis Assay 
Apoptosis is a process of genetically programmed cell death in normal cells to maintain 
homeostasis which is impaired in cancerous cells [4, 39]. Hence, the cells keep proliferating 
endlessly. In order to analyse apoptosis induction due to TQ and Dend-TQ, Annexin V/FITC-
PI staining assay was performed. Annexin V is known to bind to those cells that express 
phosphatidyl serine on the outer layer of the cell membrane, a characteristic feature of cells 
entering apoptosis [47]. This is a sign for early apoptosis. Staining with Annexin V is typically 
used in conjunction with a vital dye such as propidium iodide (PI) for identification of early 
and late apoptotic cells. Cells that are viable have intact membranes which act as a barrier 
excluding PI, whereas the membranes of dead and damaged cells are permeable to PI. 
Therefore, both Annexin V and PI negative cells are considered viable, while cells that are 
Annexin V positive and PI negative are considered in early apoptosis and cells that are in late 
apoptosis or already dead are both Annexin V and PI positive.  
The flow cytometry results in Figure 4.10 demonstrated that Dend-TQ induced apoptosis 
showed an increase in number of cells entering in apoptosis. After 24 h of treatment, the 
percentage of Annexin V-stained cells was 24.9% and 32.3% for TQ and Dend-TQ in MCF-7 
cells, respectively, which suggests there is an increase in the population of cells at early 
apoptotic stage in both types of treatment.  
However, MDA-MB-231 showed improvement inefficacy by 10 times with rise in apoptotic 
cells from ~ 6% to 52.6% (from Figure 4.11). Therefore, this increase in the early apoptotic 
cells in case of Dend-TQ, suggests an increase in therapeutic efficacy with encapsulation of 
TQ in dendrimer. A number of recent studies have reported TQ’s oxidant activity as one of the 
causes for DNA damage and ultimately leading to apoptosis [30, 48, 49]. 
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Figure 4.10 Flow cytometry analysis of Annexin V/ FITC Assay for determination of 
apoptosis in MCF-7 and MDA-MB-231 with TQ and Dend-TQ treatment for 24 h 
 
 
Figure 4.11 Representation of a percentage of apoptotic cells quantitated by Annexin V-
FITC/PI analysis of MCF-7 and MDA-MB-231cells treated with pristine TQ and Dend-TQ 
for 24 h 
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In fact, a study by Arafa et al., found that TQ mediated cell death occurred via an 
intrinsic/mitochondrial pathway, where it triggered the caspase activation leading to apoptosis 
due to TQ induced reactive oxygen species which caused oxidative stress [50]. Hence, the 
above results are in support with the literature, suggesting that TQ mediated apoptosis occurs 
via a mitochondrial pathway [29, 33, 49-51] 
 4.4 Conclusions 
In conclusion, a dendrimer based formulation encapsulating TQ and its biological activity was 
tested in vitro in this study. From the above study, it can be concluded that dendrimer 
formulation helps to increase the stability of TQ compared to pristine TQ in DMSO. 
Simultaneously, it also enhances the therapeutic efficacy of TQ with the help of controlled 
release up to 24 h. With help of characterisation techniques, it was found that G4 PAMAM 
dendrimers (0.4% w/v) showed the highest loading of 1332 μg/mL. The UV-vis spectroscopy 
showed that TQ did not change in its form but was encapsulated within the dendrimer. 
However, for further understanding the interaction between the TQ and dendrimer, FTIR and 
NMR was performed on samples. The results revealed the encapsulation of TQ in its 
nanoparticulate form within the hydrophobic pockets of the dendrimer by host-guest 
interaction. The nano-formulation was then exposed to an array of cancer cell lines which 
showed in the improvement of cytotoxicity in profiles of all cell lines with best results in a 
MDA-MB-231 (breast cancer cell lines) (Figure 4.5). To further assess the reasons for toxicity, 
in vitro apoptosis assay, Annexin V/FITC assay was conducted. The results showed increase 
in the ratio of early apoptotic cells in both the cell lines (Figure 4.10). To understand the effect 
of TQ on DNA damage, the level of ROS and change in mitochondrial membrane potential 
(DΨM) was measured in both cell lines. Results suggest an increase in levels of ROS with a 
significant change in DΨM, upon application of Dend-TQ in comparison to pristine TQ. The 
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disruption of mitochondrial membrane could lead to release of catabolic hydrolases responsible 
for DNA, lipids and protein damage along with activation of apoptosis (Figure 4.7 and 4.9).  
The sum total of all the above results suggest an improvement in the therapeutic efficacy of the 
TQ based dendrimer formulation due to small size of  dendrimers, increase in the TQ stability 
and slow sustained release of TQ for up to 24 h.  
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Chapter 5: Self-assembled nanostructures of triblock copolymer-
aspartate gold nanoparticles as TQ delivery vehicles with 
improved stability and therapeutic efficacy  
5.1 Introduction 
In the previous chapters, it was shown that nanosuspension of TQ and dendrimer encapsulated 
TQ exhibit significant anti-cancerous activity as a result of its encapsulation, which can protect 
TQ from degradation as well as its transport across the hydrophilic medium. Therefore, the 
drug delivery systems that contain hydrophobic domains are the desired candidates of 
delivering hydrophobic drugs such as TQ to the target site. There are several amphiphilic drug 
delivery systems that include surfactants, soluble polymers, lipoproteins, liposomes, and 
amphiphilic polymer based micellar systems, which have been extensively used for the drug 
delivery applications [1-4]. These amphiphilic carriers have the hydrophobic domains, which 
can be used to solubilize the hydrophobic drug for the targeted delivery and the needed 
biological action [5]. However, simple surfactants based systems, due to their high critical 
micellar concentrations (CMC), tend to be unstable under in vivo biological conditions [6]. On 
the other hand, lipoproteins and liposomes have the disadvantages of competitive binding with 
other receptors and low encapsulation and rapid release of drugs [7]. Among the 
aforementioned carriers, polymer micelles based drug delivery systems are considered as 
promising due to their higher loading of drugs, stability in blood stream, therapeutic potential 
and long term storage stability [1]. In simple terms, polymeric micelles possess hydrophobic 
core and hydrophilic shell in which the hydrophobic core provides the space for the 
encapsulation of hydrophobic drugs such as TQ.  
Among the different amphiphilic co-polymers, Pluronic tri-block copolymers have been 
studied extensively for different biological applications due to their excellent biocompatibility 
[1, 7-15]. These tri block copolymers generally have the structure of PEO–PPO–PEO block 
126 
 
copolymer, wherein PEO and PPO stands for poly(ethylene oxide) and poly(propylene oxide) 
blocks, respectively, as shown in the following figure.  
 
Figure 5.1 Structure of PEO-PPO-PEO tri-block copolymer 
The PEO units are hydrophilic in nature, while the PPO units are hydrophobic in nature. The 
number of units (denoted as x and y in Figure 5.1) are different for different kind of pluronic 
polymers because the number of units provide the hydrophilicity/hydrophobicity balance of the 
tri-block copolymer [1]. The choice of this Pluronic block copolymer for this drug delivery 
application is mainly due to its propensity to self-assemble in aqueous solutions into 
multimolecular aggregates having spherical, rod-like or lamellar morphologies which is 
specifically useful to drug delivery applications [4]. In their micellar structure in water, 
micelles core consist of hydrophobic PPO blocks and hydrophilic PEO blocks on the surface. 
The core hydrophobic PPO units in these polymeric micelles will encapsulate the hydrophobic 
drugs like TQ and can demonstrate high loading capacity, controlled release profile for the 
incorporated drug, and good compatibility between the core forming block and incorporated 
drug. The PEO corona provides an effective steric protection for the micelles and determines 
the micelle hydrophilicity, charge, the length and surface density of hydrophilic blocks. These 
properties control important biological characteristics of a micellar carrier, such as its 
pharmacokinetics, biodistribution, biocompatibility, longevity, surface adsorption of 
biomacromolecules, adhesion to biosurfaces and targetability [6]. It is also reported that 
Pluronic block copolymers promote active membrane transport of numerous compounds and 
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thus can help in overcoming multiple drug resistance (MDR) phenomena in cancer therapy 
[10].  
Among the different kinds of tri-block copolymers, PEO20-PPO70-PEO20 (denoted as P123 
from now onwards) has low critical micelle concentration and the hydrophobic-hydrophilic 
blocks ratio is suitable for the sensitization of MDR cells [12]. Batrakova et al. demonstrated 
that number of hydrophobic propylene oxide (PO) units is the critical factor for efficient 
sensitisation to chemotherapeutic drugs in KBV cell line [7]. However, these polymers do not 
have any additional functional groups for targeting, not much variation in micellar size, drug 
loading capacity and not efficient way of controlling the release of drugs. The applicability of 
these P123 micelles as drug delivery vehicles for anticancer applications (though not for 
phytochemicals) has been well studied so-far and the aforementioned factors needs to be taken 
care for the efficient anticancer applications. 
Therefore, the aim of this work is to functionalise the self-assembled nanostructures of P123 
by amino acids and gold nanoparticles by a novel method and investigate the stability of TQ 
and explore its therapeutic efficacy due to encapsulation. Since TQ is a hydrophobic drug, 
DMSO solution of TQ can be incorporated within the self-assembled structures of a 
biocompatible tri-block copolymer. Gold nanoparticles will provide rigidity to the polymeric 
micelles, therefore, they function as additional material to control the release kinetics of TQ.  
These polymer micelles were surface functionalized with amino acids such as aspartic acid 
(acidic), lysine (basic) and histidine. The major reason to use amino acids to functionalize the 
P123 surface is due to their hydrogen bonding capacity with the PEO blocks of the micelles 
[16], providing the surface PEO units with amino acid functionality that can render the surface 
more hydrophilic, biocompatible and control the release of the TQ adsorbed within the 
hydrophobic PPO core of the micelles. Additional functional role of these amino acids is their 
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ability to reduce gold ions into gold nanoparticles, which protect the drug further and provide 
rigidity to the micellar surface [5, 17].  
Since TQ is a hydrophobic drug, DMSO solution of TQ exhibit very high affinity to reside 
within the PPO units, which is hydrophobic in nature and protects TQ from any degradation. 
The amino acids and gold nanoparticles increase the surface hydrophilicity and act as barrier 
to release the hydrophobic drug slowly.  
5.2 Materials and Methods 
5.2.1 Synthesis of P123 amino acid Au micelles 
TQ, P123, Amino acids aspartic acid, lysine and histidine were purchased from Sigma-Aldrich 
and used as such without any modification. All the solutions were prepared in deionized water. 
Figure 5.2 Synthesis route of Amino acid/Gold nanoparticles functionalized P123 micelles 
for TQ encapsulation 
A 0.5 wt %/V of P123 solution was made by dissolving 1 g of P123 polymer in 200 mL of de-
ionized water. This solution was divided into four parts containing 50 mL of P123 solution. To 
the first part, 100 µM solution of TQ in DMSO (100 µL) was added and dispersed uniformly 
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by ultrasonication. This solution was kept at 37°C. To each of the remaining three P123 
solutions, amino acids aspartic acid, lysine or histidine were added individually, to maintain 
their concentration 1 mM in 50 mL.  To each amino acid containing P123 solution, aqueous 
solution of chloroauric acid was added. The concentration of the chloroauric acid was 
maintained at 2x10-4 M in the amino acid functionalized P123 solution. These solutions were 
kept at 37°C for one day until the gold nanoparticles formation. These amino acids were 
reported to reduce chloroaurate ions into gold nanoparticles, therefore the P123 micelles were 
functionalized by both amino acids and nanoparticles. Subsequently, to all the three solutions 
(P123-Asp-Au, P123-Lys-Au, P123-His-Au), 100 µM solution of TQ in DMSO (100 µL) was 
added to each and dispersed uniformLy by ultrasonication. All these solutions were kept at 
37°C and then placed in a dialysis bag for 6 h in dark to remove free TQ, amino acids and gold.  
5.2.2 UV visible spectra  
In order to investigate the presence of TQ into the P123 amino acid gold complex, the 
complexes scanned in the wavelength-range of 200-800 nm using UV/vis spectrophotometer. 
5.2.3 In vitro drug release  
In vitro drug release from TQ, and P123 Asp-Au TQ solution formulation was evaluated using 
dialysis bag diffusion method. P123Asp TQ micelles, P123 Asp-Au TQ complex or TQ 
solution, containing TQ equivalent to 3 mg, were placed in a dialysis bag (Cellophane 
membrane, molecular cut off 2000 Da). After that, the dialysis bag was immersed in 100 mL 
of PBS in a beaker. The system was maintained at 37 ± 0.5 °C under 100 rpm speed. At 
predetermined time intervals, 5 mL of aliquots were collected and the same amount of fresh 
medium was replaced to maintain the sink condition. The collected aliquots were filtered, 
diluted appropriately and analysed for the absorbance between 200-800 nm using a UV-vis 
spectrophotometer. 
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5.3 Result and discussion 
5.3.1 Physicochemical characterization  
5.3.1.1 Dynamic light scattering and Zeta Potential 
Dynamic light scattering (DLS) measurements were performed using a Malvern 4800 
Autosizer employing a 7132 digital correlator.  
Table 5.1 DLS and Zeta potential measurements of the P123 amino acid / Au NP 
functionalized micelles 
 
The light source was a He–Ne laser operated at 633 nm with maximum power output of 15 
mW. The correlation functions were analysed by cumulants method of analysis. DLS 
measurements given in Table 5.1 clearly show that bimodal distribution of P123 micelles was 
formed. The smaller size (22 nm) represents the individual micellar size and the large size 
micelle (138 nm) may be attributed to the cluster or aggregate of few micelles. However, after 
the addition of amino acids and formation of gold nanoparticles, the average hydrodynamic 
radius increased significantly for both individual micelle and aggregate of micelles size in 
comparison to P123 micelles. P123 micelles tend to form hydrogen bonds with polar molecules 
through its EO units on the surface, therefore the hydrophobic domain is known to expand [8, 
10]. This may be the reason for the increase in hydrodynamic radius of the nanoparticles. Zeta 
No Polymer micelles Hydrodynamic radius 
(nm) 
Hydrodynamic 
radius II (nm) 
Zeta Potential 
(milli volts) 
1 P123 22 138 -5.0 
2 P123-Asp 
P123-Lys 
P123-His 
P123 Asp-Au TQ 
P123-Lys-Au TQ 
P123-His-Au TQ 
35.5 
33.5 
47 
26.3 
25 
6 
-- 
171 
240 
207 
215 
94 
-3.7 
-9.8 
-12.3 
-3.34 
-12.4 
-12.3 
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potential results showed a slightly different trend, wherein P123-Asp-Au showed decrease in 
the zeta potential with respect to pure P123 and P123-Lys-Au micellar systems. This may be 
probably due to the strong hydrogen bonding between the carboxylic units of aspartic acid with 
EO units of P123, thereby decreasing the surface charge of the micelles. According to Gotchev 
et al., zeta potential can be considered as a valid parameter only if a colloid system is 
electrostatically stable. However, their study suggested that the tri-block co polymers are 
stabilised by electrostatic and stearic forces. However, in absence of electrostatic charge the 
tri-block copolymers remained stable.  Hence, the low zeta potential values do not necessarily 
indicate instability of the nanoformulation [18].  
5.3.1.2 UV-Visible Spectral Results 
 
Figure 5.3 UV-Visible spectral data of P123-Amino acid, P123-Amino acid-Au nanoparticles 
(dotted lines) and after loading of TQ (solid lines) 
Thymoquinone is known to absorb between 300-350 nm in the UV region and gold 
nanoparticles exhibit its strong surface plasmon resonant absorption at 520 nm; therefore the 
formation of nanoparticles as well as TQ incorporation can be studied using UV-Visible 
spectroscopic technique. Figure 5.3 shows the UV-Visible spectral data of P123 with aspartic 
acid, histidine and lysine amino acids (dotted lines in all three panels) before and after addition 
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of TQ. In all the three cases, it is clearly seen that there is a strong absorption between 300-350 
nm due to the presence of thymoquinone. As mentioned earlier, P123 has hydrophobic core 
and addition of DMSO solution of TQ preferentially occupy these hydrophobic domains of 
P123-Amino acid micelles. In the case of lysine, appearance of two bands clearly says that TQ 
exist is in its native form as well as its isomeric form due to the basicity of lysine amino acid. 
Lysine is also a hydrophobic amino acid, therefore, a competitive adsorption may occur 
between lysine and TQ in the hydrophobic domains of P123 micelles. Since amino acids are 
known to reduce gold ions to form nanoparticles, P123-Amino acid micelles can form 
nanoparticles on their surface by reducing the gold ions. This was clearly demonstrated by the 
presence of strong surface plasmon resonant absorption of gold nanoparticles around 530 nm 
in the visible region in all three amino acid functionalized P123 micelles (dotted lines). 
Addition of TQ to these P123-Amino acid-Au nanoparticles, lead to the incorporation of TQ, 
which was confirmed by the presence of strong absorption in the region between 300-350 nm 
(marked with an arrow).   
5.3.1.3 Transmission Electron Microscopy (TEM) 
 
Figure 5.4 TEM images of P123-Asp-Au, P123-Lys-Au and P123-His-Au micellar systems 
TEM images of these P123-Amino acids-Nanoparticles were taken using JEOL 1010 TEM 
instrument, operated with the 100 KV accelerating voltage. Samples were made by drop-
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casting of the materials on the surface of carbon-coated copper grids. Figure 5.4 shows the 
TEM images of the P123-Asp-Au, P123-Lys-Au and P123-His-Au micellar systems, wherein 
the formation of micellar structures and the nanoparticles formation were clearly seen.  
5.3.2 Biological characterization  
5.3.2.1 Comparison of dose dependent toxicity of P123 Asp-Au TQ in breast cancer cell 
lines  
In the previous Chapter 4, MCF-7 and MDA-MB-231 were found to be the most sensitive cell 
lines, hence MTT assay was performed with aforementioned amino acid gold nanoparticles 
functionalized P123 micelles loaded with TQ.  Cell viability studies of MCF-7 and MDA-MB-
231 cell lines were carried out using MTT assay for the period of 24 hours and the results are 
shown in Figure 5.5. Pure TQ was also used as reference and the cell viability was plotted 
against the concentration of TQ. As compared to pure TQ, all the TQ loaded amino acid gold 
nanoparticles functionalized micelles have shown enhanced cytotoxicity at all concentrations. 
The results from the Figure 5.5 suggest that P123 Asp-Au TQ showed the highest decline in 
cell viability in both the cell lines with respect to pristine TQ. As mentioned in the Chapter 2 
section 2.3.1, 10 µM TQ concentration showed high cell viability and was responsible for the 
initiation of EMT in the MCF-7 cells. Hence, it was chosen as a desired concentration for 
further biological characterization.  
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Figure 5.5 Cell viability studies of the three different amino acid (aspartate, histidine and 
lysine) functionalized P123 micelles loaded with TQ for MCF-7 (left) and MDA-MB-231 
(right). Data are mean ± Standard error from three independent experiments 
Among all the three amino acid functionalized P123 micelles, the aspartic acid functionalized 
micelles were found to exhibit higher cytotoxicity at both concentrations. Lysine and Histidine 
have additional basic functional groups and they may contribute or compete with the biological 
action of TQ. Therefore, aspartic acid functionalized P123 micelles were chosen as TQ drug 
delivery vehicles for the detailed studies. Both cell lines were exposed with increasing 
concentrations of the pristine TQ and P123 Asp-Au TQ in a dose dependent manner for 24 h. 
The graphs from Figure 5.6 depict cytotoxicity of only P123 Asp-Au TQ in MCF-7 (image on 
the left) and MDA-MB-231(image on the right) with respect to pristine TQ after 24 h treatment 
for a simplification of enhanced therapeutic response. The response at higher concentrations 
remained almost the same as that of TQ in MDA-MB-231 cells. Both graphs in the Figure 5.5 
includes the toxicity of each separate component required for the synthesis of polymer complex 
which include P123, Aspartate (amino acid), P123 with aspartate, P123 with aspartate 
decorated with gold. In Figure 5.6, P123 Asp-Au TQ showed a steady decline in cell viability. 
In MCF-7 cells, the pristine TQ shows about 30% decrease in cell viability at 10 μM; however 
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P123 Asp-Au TQ showed decrease in viability to 55% in comparison to the untreated sample. 
Complete cell death was seen in the MCF-7 cell at 25 μM due to P123 Asp-Au TQ instead of 
that observed in TQ at 100 μM.    
In the case of MDA-MB-231, the cell viability due to pristine TQ at 10 μM treatment shows 
only 58% decline in cell viability with regards to control sample. On other hand P123 Asp-Au 
TQ shows significant decline of about 42% with regards to. These results clearly suggest that 
even though both cell lines get affected due to encapsulation of TQ; MDA-MB-231 is more 
sensitive to P123 Asp-Au TQ in comparison to MCF-7 cells. The reduction of cell viability at 
most concentrations of TQ also indicates improvement in the efficacy of the TQ. The reason 
behind better efficacy could be maintenance of integrity of TQ by encapsulation within the 
polymeric capsules [8, 9].   
Another observation that can be made from the two graphs is that the empty micelles with all 
the components except TQ, show very low toxicity in both breast cancer cell lines in 
comparison to P123 Asp-Au TQ. This clearly suggests that the toxicity obtained was directly 
from the TQ loaded in the nanomicelles and enhanced effect suggested that the stability of TQ 
was improved in comparison to TQ in the solution.   
The cytotoxicity profile of the each individual component used in synthesis of the polymeric 
micelles was additionally done as seen in Figure 5.6. The aim was to check if all the 
components were biocompatible in the cells. Most components showed negligible cytotoxicity 
in MCF-7 cell and MDA-MB-231 at even high concentrations.  
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Figure 5.6 Dose dependent cytotoxicity of breast cancer cells due to pluronic 123, Asp, P123 
Asp, P123 Asp-Au, P123 Asp-Au TQ and pristine TQ treatment after 24 h. Data are mean ± 
Standard error from three independent experiments 
However, TQ with encapsulation in different types of carrier has shown increase in stability 
along with improvement in therapeutic efficacy. In order to provide an insight for further 
understanding behind improvement in efficacy, drug release study was performed. 
5.3.2.2 In vitro drug release 
The graph in the Figure 5.7 shows a comparison of TQ’s release profile from P123 Asp TQ 
(without gold nanoparticles) and P123 Asp-Au TQ (with gold nanoparticles) plotted against 
pristine TQ in the solution. The results suggested that TQ from the solution was released within 
4 h which meant that, it is readily available to the cells. However, there is a decrease in the 
release of both formulations. P123 Asp TQ is amino acid conjugated P123 micelles and P123 
Asp-Au TQ comprises of TQ loaded amino acid conjugated P123 micelles with gold 
nanoparticles. From the graph, it is observed that P123 micelles show the slowest release with 
respect to micelles consisting gold nanoparticles followed by polymeric micelles with gold 
addition. This is a clear indication that the gold nanoparticles formed due to reduction of gold 
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chloride by aspartate, facilitates slow and sustained release of TQ. Furthermore, the results in 
the cytotoxicity graph (Figure 5.6) also reflect a possibility for increased therapeutic efficacy.  
 
Figure 5.7 In silico release of TQ from TQ solution, P123 Asp TQ and P123 Asp-Au TQ at 
37°C in PBS up to 24 h 
5.3.2.3 Intracellular ROS generation: 
The results from anti-proliferative assay suggested that Asp-Au-TQ is more potent and anti-
cancerous towards breast cancer cells. However, the assay does not provide an insight into the 
mode of action for increase therapeutic efficacy. Hence the formulation was checked, if the 
ROS pathway was affected or not. The cells were treated at the concentration of 10 µM for TQ 
and P123 Asp-Au TQ and then were stained with carboxy-H2DFFDA. After the dye crosses 
the cell membrane, the process of deacetylation involved with cellular esterase occurs in the 
cell and the non-fluorescent compound formed within the cell reacts with the carboxy-
H2DFFDA within the cell to give a fluorescent signal.  
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Figure 5.8 Confocal micrographs of fixed cells treated with carboxy-DCFFDA to observe 
increase in levels of ROS generation in MCF-7 and MDA MB-231: Control, Pristine 
TQ and P123 Asp-Au TQ (Scale bar: 50 μm) 
 The amount of ROS generation increased in the cells in the following order:  
Untreated cells < TQ < P123 Asp-Au TQ  
In case of the quantitative method performed on the fluorescence spectrophotometer includes 
live cell measurement where the treated cells were dislodged and stained with carboxy-
H2DFFDA. The fluorescence intensities obtained from all three samples normalized against 
the untreated cells and plotted as function of increase in amount of ROS generated. The results 
in the Figure 5.7 (a) suggest an increase in ROS generation in both samples viz. TQ and P123 
Asp-Au TQ. This result was further established with the help of quantitative analysis using a 
fluorescence spectrophotometer. The fluorescence intensities obtained from all three samples 
were normalized against the untreated cells and plotted as function of change in ROS 
generation. The elevation in the levels of ROS generated by P123 Asp-Au TQ compared to 
pristine TQ was noted higher in MDA-MB-231 cells than in MCF-7 cells (Figure 5.9). There 
was approximately 1.5 fold change in the intensity in MDA-MB-231cells with respect to 
untreated sample whereas only 0.75 fold change was seen in case of MCF-7 cells. The results 
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were in agreement with the fluorescent micrographs indicating a rise in the generation of ROS 
in significant amounts with P123 Asp-Au TQ treatment.  
 
Figure 5.9 The graph represents fluorescence intensities obtained from all three samples 
normalized against the untreated cells and plotted as function of increase in amount of ROS 
generated. Data are mean ± Standard error from three independent experiments 
Current literature acknowledges the presence of cross talk between the ROS and DΨM. As 
listed above, one of the harmful effects involve change in the membrane potential of 
mitochondria. Hence, the next step was to check if DΨM was affected by the treatment, as 
literature suggests that cancer cells tend to have higher ROS compared to normal epithelial 
cells.   
5.3.2.4 Mitochondrial Membrane potential (DΨM) 
The change in the mitochondrial membrane potential was assessed in MDA-MB-231 in 
presence of TQ and P123 Asp-Au TQ. After the 24 hour incubation the cells were washed and 
treated Rh123. The fluorescence micrographs and intensities were captured for qualitative and 
quantitative analysis respectively.  
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The results from the Fig 5.10 comprise of the confocal micrographs show Rh123 stained cells 
in presence of TQ and P123 Asp-Au TQ. The quantitative data from the graph in Figure 5.11 
suggests a steady decline in the mitochondrial membrane potential upon P123 Asp-Au TQ 
treatment in both cell lines with about 30% decrease in MCF-7 and about 55% in MDA-MB-
231. These results exhibit a change in the membrane potential of mitochondria. The dye 
specifically gets accumulated in the mitochondria with intact membrane. 
 
Figure 5.10 Confocal micrographs of live cells treated with Rhodamine123 to observe the 
change in DΨM at different treatments in MCF-7 and MDA MB-231: Control, 
Pristine TQ and Asp Au-TQ (Scale bar: 50 μm) 
The decline in fluorescent intensities is a sign for change in DΨM across the mitochondrial 
membrane, which could lead to leaky structure of the mitochondria. The leaky structure may 
lead to leakage of catabolic hydrolases, proteases and nucleases that are required to tackle the 
reactive oxygen species generated within the mitochondria [19-21]. The ROS is usually kept 
in control by their specific inhibitors or by sequestration of their activators. This disruption of 
the mitochondrial membrane occurring due to change in the membrane potential, allows the 
escape of activators that exert pressure on both vital and lethal functions required for 
maintenance of cells. 
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Figure 5.11 The graph represents fluorescence intensities obtained from all three samples 
normalized against the untreated cells and plotted as function of change in DΨM. Data are 
mean ± Standard error from three independent experiments. 
The termination of mitochondria’s biological redox function occurs with release of catabolic 
enzymes that lead to cell death. As mentioned in the previous Chapters 3 and 4, the particular 
stage is also known as “a point of no return”. The initiation of apoptosis in the cancer cells 
occur which eventually leads to DNA damage and finally destruction of the cell [22]. It is also 
evident from the above results that cross talk between ROS and DΨM is very important to 
maintain functional mitochondria in the cells [4, 22, 23]. If changes in DΨM are seen in the 
cells due to TQ and its nano-formulation, it would be ideal to investigate the initiation of early 
apoptosis in order to approve the mitochondrial dependent pathway for cell death. 
5.3.2.5 Apoptosis Assay: 
With enhanced ROS levels and change in DΨM and results from Chapters 3 and 4 suggesting 
an increase in levels of apoptosis upon usage of drug delivery vehicle. The relationship between 
cell proliferation and apoptosis is important for maintaining normal tissue homeostasis and 
development [24, 25]. However, cancer cells strongly depict an anti-apoptotic feature leading 
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to uncontrolled proliferation of cells. The disruption caused within genetically defined 
programmed cell death would be a major cause for endless proliferation of cancerous cells. 
There a number of reasons for apoptosis to occur in a cell [17, 25, 26]. One such reason can be 
associated with increase in ROS levels, which lead to change in DΨM [27-29]. Hence cells 
were checked for apoptosis using Annexin V/FITC-PI staining assay as discussed previously 
in Chapter 3. The degree of apoptosis induced by the P123 Asp-Au TQ on MCF-7 and MDA-
MB-231 cell lines investigated by Annexin V/Propidium Iodide (PI) dual staining facilitates 
the detection of live cells (Q4; AV-/PI-) early apoptotic cells (Q3; AV+/PI-), late apoptotic 
cells (Q2; AV+/PI+) and necrotic cells (Q1; AV-/PI+). In MCF-7 cells (Figure 5.13), apoptotic 
cell population rose from 0 to 24.9 % after pristine TQ treatment (10 µM). However after the 
treatment of P123 Asp-Au TQ (10 µM equivalent TQ) the apoptotic cells population rose to 
58%, indicating 2 fold rise in comparison to the untreated.  
The results were in agreement with the levels of ROS and change in DΨM observed in both 
cell lines. From previous Chapters 3 and 4, MDA-MB-231 was found most sensitive which is 
similar to the results in this Chapter as well. This not only indicates Asp Au-TQ shows an 
increase in efficacy when compared to that of pristine TQ but also indicated that the cell death 
due to nano-formulation might be due to initiation of apoptosis via a mitochondria based 
pathway. 
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Figure 5.12 The flow analysis of Annexin V /FITC Assay for determination of apoptosis in 
MCF-7 and MDA-MB-231 upon treatment with 10 µM TQ and P123 Asp Au -TQ treatment 
for 24 h 
 
 
Figure 5.13 Graphical representation of percentage apoptotic cells (Annexin V +ve) with 
respect to different treatments 
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5.5 Conclusion: 
In summary, a novel polymer micelles based on aspartate-polymer conjugate coated with gold 
have been prepared, partially characterised and evaluated for their cytotoxic activity against 
two human breast cancer cell lines. The TEM images confirm the formation of capsules coated 
with gold nanoparticles. The results showed that nanoformulation exhibited remarkable cell 
growth inhibition activities on different cancer cells. In addition, they enhance the degree of 
apoptosis in both cell lines by causing a significant elevation in ROS production which in turn 
disrupts the mitochondrial membrane releasing catabolic enzymes responsible for initiation of 
apoptosis. Overall, these results demonstrate that the P123 Asp-Au TQ has the potential to be 
developed as nano-carrier for encapsulating TQ and other phytochemicals to enhance their 
therapeutic effect and their stability.  
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Chapter 6: Comparative analysis of different drug delivery 
platforms for TQ 
6.1 Introduction (re-visiting the problems of TQ): 
In vitro studies have shown that TQ has strong anticancer effect [1-9], which was also evident 
in the case of in vivo models such as mice and rats [3, 10]. However, the sole human cancer 
clinical trial using pristine TQ did not show any significant therapeutic effect [11]. This is 
possibly due to the several challenges mentioned in Chapter 1, such as the lipophilic nature of 
TQ, which creates a problem of solubility that could lead to low bioavailability. In the case of 
oral administration of TQ, it bio-transforms to a hydroquinone due to the activation of phase 2 
enzymes in the liver, making it less bioavailable to the body [12]. The issue of bioavailability 
suggested that the concentration of TQ reaching a tumour in the body, might be much lower 
than the dose administered [13-15]. Hence, this study was conducted to understand the effect 
of sub-toxic concentrations of TQ on MCF-7 cells.  
In Chapter 2, it was observed that low concentrations of TQ reduce E-cadherin (E-cad) 
expression along with destruction of the cadherin-catenin complex. This leads to the 
translocation of β-catenin to the nucleus, which activates the transcription of CdK2. This, in 
turn, triggers increased proliferation of MCF-7 cells and is also associated with activation of 
epithelial-mesenchymal transition (EMT). This poses a serious problem, as it increases the 
aggressiveness of cancer and activates metastasis.  To mitigate this problem, three different 
nanoformulations were used to increase the effectiveness of TQ against cancer cells. 
The objective of this chapter is to provide a comparative analysis of the three different 
nanoformulations used in this thesis, to understand the most effective nanoformulation against 
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breast cancer. This chapter also highlights the effect of TQ nanoformulations on E-cad 
reduction in association with EMT activation. 
6.2 Materials and Methods  
The materials and method used for flow cytometric analysis of E-cad expression in MCF-7 
cells is as described in Chapter 2 section 2.2.6.  
6.2.1 Calculating IC50 and IC80 for each of the nanoformulations 
The concentration at which the compound (TQ) reduces the cell viability by half (50%) is 
known as inhibitory concentration (IC50). Initially the IC50 was calculated using Probit 
software (Israel) that utilised the cytotoxicity results obtained in Chapters 2-5. In order to 
generate IC80 values, a trend line was plotted to generate an equation of the line for the three 
nanoformulations in each cell line. The slope was determined from the equation: 
𝑦 = 𝑚𝑥 + 𝑐 
Where m: slope of the line, c: intercept of (y, x) 
The slope values and their respective IC50 values obtained were used as inputs to determine 
the IC50/EC80 (inhibitory concentration) using calculator from Graphpad® quickcalcs 
(GraphPad Software, Inc. USA) to calculate IC50. The IC80 values were also calculated in 
similar manner for all the nanoformulations.  
6.3 Results and discussion 
6.3.1 Comparative analysis on the basis of physico-chemical characterisation 
Table 6.1 enlists the characteristics of each of the nanoformulations used for delivering TQ. 
According to the results, TQ nanosuspension had the smallest hydrodynamic radius and amino 
acid functionalised polymer micelles were the largest.  
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The surface charge is known to play an important role with regards to uptake of 
nanoformulations in cells, hence zeta potential is an important characterisation measurement 
used for determination of the surface charge. It is also an important parameter for predicting 
the long term colloidal stability of the nanoformulation [16]. Based on zeta potential 
measurements, nanosuspensions showed better stability in comparison to dendrimers and 
amino-acid polymeric micelles.  
Table 6.1 Comparison of different nanoparticulate systems used for delivering TQ 
 Nanosuspension 
(TQ–NSP B) 
Dendrimers 
(Dend-TQ) 
Amino acid 
polymer micelles 
(P123 Asp Au-TQ) 
 
DLS  diameter (nm) 
 
11.2±0.78 
 
15.97±1.7 
 
104.86±1.3 
Zeta Potential (mV) -16.3±2.1 -14.1±0.9 0.603 ± 6.93 
Type of Interaction 
with TQ 
 
Hydrophobic  
(Non-polar) 
Host-guest 
(Electrostatic)  
Hydrophobic  
(Non-polar) 
Drug loading  
 
% Drug release in 12 h 
N/A 
 
N/A 
333 μg/mL 
 
81% 
800 μg/mL 
 
86.3% 
 
In the case of drug loading studies, it can be observed that the results correspond to above size 
distribution data. Since dendrimer has a smaller hydrodynamic radius in comparison to P123 
Asp-Au TQ micelles the amount loaded in dendrimers was much lower than the micelles. The 
drug loading and release studies were not applicable for nanosuspension as it was the 
pure/pristine drug that was transformed to nanometre sized particles.  
6.3.2 Comparative analysis on the basis of cytotoxicity profile 
In order to perform a comparative analysis of all three nanoformulations on the basis of anti-
proliferative effect and to understand the kinetics of TQ degradation after encapsulation, cell 
viability assay of each nanoparticle with equivalent amount of loaded TQ was performed. 
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Figure 6.1 shows a comparison of the dose dependent cytotoxicity of each nanoformulation in 
comparison to pristine TQ, in two breast cancer cell lines - MCF-7 and MDA-MB-231 after 24 
h. It should be noted that in the absence of TQ, the dendrimers (~85% viability) and P123 Asp-
Au micelles (~80% viability) showed no significant toxicity to both cell lines tested.   
In MCF-7 cells (Figure 6.1 a), at relatively lower concentrations (50 µM) all three TQ 
nanoformulations showed complete cell death within 24 h, which was only seen at 100 µM in 
case of pristine TQ. Both cell lines were found to be most susceptible to P123 Asp-Au TQ 
formulation with ~65-70% decrease in viability at 10 µM equivalent TQ concentration. Dend-
TQ and P123 Asp-Au TQ, however, showed similar effectiveness at 10 µM equivalent TQ 
concentration (Figure 6.1 a).   
Another interesting finding observed in Figure 6.1 is, that while TQ-NSP B proved to be less 
effective in MCF-7 cells up to 25 µM equivalent TQ, it showed significant toxicity in MDA-
MB-231 cells. TQ-NSP B showed the highest decline in the cell viability of MDA-MB-231 by 
80% at a 10 µM TQ equivalent concentration, suggesting it is the most effective formulation 
in case of MDA-MB-231 cells.  
The resistance to TQ-NSP B is not well understood in case of MCF-7, however, one reason 
could be the morphology of MCF-7 cells. As discussed earlier in Chapter 2 section 2.4, the 
morphology of the cells plays an influential role in cancer therapy. MCF-7 cells are known to 
preserve their characteristics of differentiated mammary epithelium in in vitro conditions. As 
seen in Chapter 2 Figure 2.3, MCF-7 cells grow in domed shaped colonies, that tightly adhered 
to each other, allowing less surface area exposed for the penetration of certain 
nanoformulations [17]. However, this was not the case for MDA-MB-231 cells with regards to 
cell morphology; hence this cell line was mose susceptible to TQ-NSP B. These results also 
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suggest TQ-NSP B as a better drug delivery platform for highly metastatic cells such as MDA-
MB-231 cells. 
Taken together, all the three nanoformulations showed an enhanced response in comparison to 
pristine TQ. The decline in cell viability was observed in each system at almost all TQ 
concentrations with complete cell death at ~50 µM TQ.  
Keeping in mind the outcomes from the above analysis, an experiment was devised in order to 
explore if the TQ in its nanoparticulate form, at low concentrations, could lead to activation of 
EMT, eventually leading to metastasis.  
 
Figure 6.1 Dose dependent cytotoxicity of drug delivery systems viz. dendrimer (Dend-TQ), 
P123 based amino acid capsules (P123 Asp-Au TQ) and nanosuspension (TQ-NSP B) in (a) 
MCF-7 and (b) MDA-MB-231 cells after 24 h. Data are mean ± Standard error from three 
independent experiments 
6.3.3 Flow cytometric analysis for E-cad expression in MCF-7 cells 
The cytotoxicity assay indicated an improvement in the stability and efficacy of TQ, especially 
at lower concentrations, as reflected in Figure 6.1. However, it is not known if low TQ 
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concentrations within the encapsulated nanoformulations would show activation of EMT, 
similar to lower concentrations of pristine TQ (Chapter 2, Figures 2.2.6 and 2.2.7). In order to 
address this, a 10 µM concentration of pristine TQ in MCF-7 cells, which showed 80% viability 
with a marked EMT activity, was selected as a reference point. The next part of the 
investigation involved determining the relative concentration of TQ, in each nanoformulation, 
at which the cells showed 80% viability (IC80). The value for each of the nanoformulation 
were calulated as follows: Dend-TQ (3.5 μM), TQ NSP-B (9.72 μM) and P123 Asp-Au TQ 
(4.25 μM). After the IC80 values were generated for each nanoformulation, MCF-7 cells were 
treated and assessed for viability to confirm the IC80 values obtained from the above 
mentioned calculations.  
The results showed ~80% viability (from Figure 6.2) for each of the nanoformulation, which 
was similar to that of prisitine TQ, indicating that the calculations were accurate. The next step 
was to assess the expression of E-cad via flow cytometery. The histograms in Figure 6.3 consist 
of mean flourscence intensities (FITC-A) plotted against the cell counts. The histograms 
typically show two peaks which are designated for two separate populations of E-cad, namely 
FITC-A (+ve) or  FITC-A (-ve). The FITC A+ve population represents an E-cad positive 
populations and the FITC A–ve represents an E-cad negative population. The populations are 
represented by their respective peaks in the histograms, indicating the percentage of cells in 
each population.  
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Figure 6.2 The bar graph represents the cell viability after treatment with in MCF-7 cells 
after treatment with TQ along with an untreated control, 10 μM TQ treatment (green) and at 
titrated TQ concentrations of the three nanoparticles viz. Dend-TQ (3.5 μM), TQ NSP-B 
(9.72 μM) and P123 Asp-Au TQ (4.25 μM). Data are mean ± Standard error from three 
independent experiments. 
The result from the first histogram [Figure 6.3 (a)] represent cells with no treatment of TQ, 
showing 87% of positive and 13% of negative E-cad populations. These cells are considered 
to exhibit stable E-cadherin expression. 
After the treatment with 10 µM pristine TQ, the cells showed substantial changes in both 
populations [Figure 6.3 (b)] with a rise in the negative (FITC A–ve) population from 13% to 
64% and a decrease in the positive population from 87% to 36%. This suggests that there is an 
increase in the number of cells with very low or negligible amounts of  E-cad expression and 
is discussed in detail in Chapter 2, section 2.2.6.  
TQ-NSP B [Figure 6.3 (d)] showed a negative population of 59% and a positive population of 
41%, which was similar to pristine TQ [Figure 6.3 (b)]. If the cell viability results were to be 
taken into consideration, it would be observed that MCF 7 cells showed the same viability with 
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both, TQ-NSP B and pristine TQ (Figure 6.1 (a). This could explain the similar trend in E-cad 
population between these two treatments.  
 
Figure 6.3 The flow cytometery graphs obtained by flow cytometery analysis represents the 
mean fluorescence intensity of  in MCF-7 cells after treatment with TQ along with an (a) 
untreated control, (b)10 μM TQ treatment and at calculated TQ concentrations of the three 
nanoparticles viz.(c) Dend-TQ (3.5 μM), (d) TQ NSP-B (9.72 μM) and (e) P123 Asp-Au TQ 
(4.25 μM) 
The histogram obtained after the treatment with Dend-TQ and P123 Asp-Au TQ (Figure 6.3 c 
and e)  showed a similar response, where the negative populations rose to 73% and 77% 
respectively and the positive populations decreased to 27% and 23%, respectively. This 
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suggests that low concentrations of TQ could be responsible for the decline in E-cad, which 
could activate  the process of EMT and thereby metastasis in cancer cells.  
6.4 Conclusion:  
The overall results obtained from this chapter help us to evaluate the three nanoformulations 
on the basis of their physicochemical characterisations and biological activity on two breast 
cancer cell lines. The characteristics that were evaluated included DLS, zeta-potential and drug 
loading and release. The size of the nanoformulations increased in the following order: 
TQ-NSP B < Dend-TQ < P123 Asp-Au TQ 
The smallest of all the nanoformulations was TQ-NSP-B followed by Dend-TQ and P123 Asp-
Au TQ. The dendrimer formulation showed the best results in term of drug release after 12 h. 
The in vitro release for all the nanoformulations was much better when compared to pristine 
TQ dissolved in solution. This suggests that encapsulation not only provided greater stability 
to TQ, but a slow sustainable release of TQ would be more effective for a relatively longer 
time. 
In MCF-7 cells, P123 Asp-Au TQ and Dend-TQ showed higher efficacy in comparison to TQ-
NSP B. However, in case of MDA-MB-231, TQ-NSP B showed a higher efficacy from 10 µM 
onwards in comparison to other nanoformulations. The cytotoxic profile of Dend-TQ and P123 
Asp-Au TQ in cancer cells were consistent in both cell lines with effective results being 
observed at lower concentration than 10 µM TQ.  
From the overall results, it can be deduced that at sub-lethal concentration of TQ, in any 
condition, whether encapsulated or in pristine form, can lead to decline in E-cadherin 
expression and in-turn lead to transition of epithelial cancer cells into mesenchymal phenotype. 
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 Chapter 7: Summary, conclusion and future prospects 
7.1 Summary and conclusion 
With advancement in cancer medicine and therapy in last few decades, Cancer still remains the 
leading cause of death across the world. Since last four decades breast cancer therapy has 
encountered some important changes in screening, treatment and prevention but there is still a 
large room for improvement in the field [1-3].  
Currently, a combination of chemotherapy (streamline therapy) and radiation (adjuvant 
therapy) is still the treatment of choice for breast cancer; however, it is often accompanied by 
adverse effects which significantly reduce reduce the quality of patient's life. Hence, there is a 
need for an alternative for chemo-drugs in order to mitigate the above mentioned problems.  
One such alternative involves the use of natural dietary phytochemicals which have been 
nominated for epidemiological and pre-clinical, early clinical studies for the treatment of 
cancer such as curcumin, epigallocatechin, capsaicin, thymoquinone and many more [4-7]. 
Phytochemicals usually exhibit low side effects and exhibit pleiotropic behaviour which makes 
them a suitable candidate for use as an alternative to chemotherapy which can eventually lead 
to the betterment of patient’s health and for improvement of therapeutic efficacy 
simultaneously.  
As mentioned above the pleiotropic nature of these phytochemicals makes them a good 
candidate for cancer therapy. Thymoquinone (TQ) is one such phytochemical that forms a 
major constituent of the volatile oils obtained from the black seed or black cumin. It has been 
more than 50 years since the identification of thymoquinone in the oils [8, 9]. Several reports 
suggest TQ to be anticancer and anti-inflammatory in nature. Most of the literature exhibits TQ 
as a cytotoxic agent or pro-apoptotic agent at high concentrations [10-17].  
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The key aspect of this thesis has been to increase the understanding of the mechanistic aspects 
of TQ and make an attempt to shed light on the changes in the biochemical pathway of TQ’s 
activity at lower concentrations in cancer cells.  
In Chapter 2, cytoxicity assay was used to identify the cell line most sensitive to TQ, by 
performing dose dependent toxicity studies on four cancer cell lines. The results obtained 
suggested that TQ was effective against all four cancer cell lines; however, both the breast 
cancer cell lines (MCF-7 and MDA-MB-231) showed the higher sensitivity to TQ. 
For a better understanding of TQ and its effect at low concentrations in cancer cells, MTT assay 
was performed in dose and time dependent manner. Even though the results indicate that TQ 
was toxic to cancer cells at higher concentrations at all the three time points viz. 24, 48 and 72 
h, at lower concentrations, it exhibited time dependent recovery. Therefore, it was not only 
important to study/explore the above effect but also develop an undertstanding at the molecular 
level in the cancer cells. For evaluation of TQ toxicity in a qualitative manner, a morphological 
assay of MCF-7 and MDA-MB-231 was performed with 3 concentrations of TQ (viz. 10, 25 
and 50 μM). The cells changed in morphology upon TQ treatment. At 10 μM the cells started 
to round off at the edges due to membrane ruffling. This indicated that TQ might be affecting 
the extracellular adhesion protein as well as reorganizing the cytoskeleton. At high 
concentration it was clearly seen that the cells were separated from colonies and rounded with 
a few floating cells. MCF-7 is an adherent cell line and rounding off and getting detached from 
the substrate indicates cell death. This is considered as one of the hallmarks of cell death in 
epithelial cancer cells [18, 19].  
The change in morphology is associated with reorganization of the cytoskeletal proteins. The 
cytoskeletal reorganization within the cells occurring at low concentrations of TQ was 
observed by probing F-actin fibre (polymeric actin fibres involved in structure and motility of 
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the cells) and vinculin (focal adhesion protein). Generally, F-actin fibres in control/untreated 
MCF-7 cells were randomly distributed and vinculin was localized towards the edges of cells 
at focal adhesion points [20]. However, after TQ treatment there was a visible reorganization 
of both proteins with change in the morphology of cells which showed bipolar characteristics. 
The F-actin was aligned towards the two poles of the cells and amount of vinculin had less 
localization at the focal adhesion points. The above evidence suggested that the cells were in a 
migratory state. The feature for cells becoming bipolar also suggests that possibility of cells 
becoming metastatic in nature  [20, 21].  
In order to understand the effect of change in the morphology and the reorganization of 
cytoskeletal proteins; it was necessary to evaluate the expression of E-cad (highly expressed in 
MCF-7 cells), a cell surface transmembrane glycoprotein which is a key protein for Ca2+ 
dependent cell-cell adhesion. It plays an important role as an inhibitor for migration and 
motility in cells [21, 22]. Since the loss of this protein is associated with the beginning of 
migratory pathway for the cells, it was considered as good indicator for migration. In order to 
determine the effect of TQ on the motility and migration of MCF-7 cells, confocal microscopy 
and flow cytometery studies suggested the loss of E-cad from the cells. The results clearly 
indicated that E-cad was affected due to TQ and its degradation was further confirmed by 
validating the translocation of β-catenin into nucleus with the help of chromatin immuno 
precipitation (ChIP) assay. ChIP assay results suggested that β-catenin, was localised in the 
nucleus after the destruction of the CCC. The results also confirmed that sub-lethal doses of 
TQ lead to an increase in CdK2 production, which results from in β-catenin translocation into 
the nucleus, leading to the degradation of the CCC. Since CdK2 is known to increase cell 
proliferation [23-25], the ChIP assay results indicate that low concentrations of TQ could 
exhibit a pro-cancerous effect. 
162 
 
Destruction of cadherin-catenin complex (CCC)has not only been associated with loss of cell 
polarity leading to cell death, but also with activation of the migratory machinery leading to 
epithelial to mesenchymal transition (EMT) of the cells. This phenomenon is known to enhance 
cancer progression and metastasis [18, 21, 26, 27]. Hence, the above results suggested that a 
sub-lethal dose of TQ may have a pro-cancerous effect through EMT of cancer cells.  
All of the above led to the identification of a new mode of action of TQ in breast cancer cells, 
which lead to lysosomal degradation of E-cad followed by destruction of CCC.  
If low concentration of TQ could possibly initiate EMT, the question that would arise from this 
study is would it be possible to increase the efficacy of these phytochemicals for better 
therapeutic efficaeffective treatment against breast cancer cells?   
The use of TQ has some limitations which include poor stability and bioavailability within the 
human body; hence TQ has not been a front runner for application in chemotherapy. In an in 
vitro environment, TQ comes in direct contact with the target cells, however, in an in vivo 
environment, it has to cross several barriers such as membrane permeability, low pH in stomach 
and insufficient time for absorption thereby losing its activity due to degradation, before 
reaching the target site and this in turn leads to low availability of TQ at the target site [28-30].  
The therapeutic efficacy of drugs and phytochemicals is most often reduced due to its 
incapability to gain access to the site of action due to its insolubility in aqueous environment 
or degradation before reaching the target site [28, 31-33].  
To address low bioavailability and improved therapeutic efficacy, three different 
nanoformulations were synthesized and characterized, wherein TQ was either encapsulated/ 
conjugated to an appropriate carrier to prevent degradation, thereby ensuring delivery of TQ to 
the target in its intact form, enhancing its therapeutic efficacy. 
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Nanosuspension was the nanoformulation of TQ that was employed to increase the efficacy in 
the breast cancer cells. TQ, in presence of a surfactant d-α-tocopherol polyethylene glycol 1000 
succinate (TPGS), was converted into its nanosuspension (Chapter 3). This formulation when 
tested on breast cancer cell lines showed increase in therapeutic efficacy at low concentrations 
of TQ.  
Dendrimers are monodisperse, macromolecular structures with globular polymeric architecture 
having several unique advantages over conventional drug delivery systems [34, 35]. In Chapter 
4, the dendrimers were loaded with TQ and tested for efficient delivery of biologically active 
TQ to the breast cancer cells. The dendrimers loaded with TQ showed increase in therapeutic 
efficacy at lower concentrations of TQ which suggested that increase the half-life of the TQ 
due to encapsulation within the dendrimer pockets. The results suggested an improvement in 
the therapeutic efficacy of the TQ based dendrimer formulation due to small size of dendrimers, 
increase in the TQ stability and slow sustained release of TQ for up to 24 h.  
In Chapter 5, another drug delivery system was based on Pluronic 123 micelles were used in 
order to increase stability and explore its therapeutic efficacy due to encapsulation. The aim 
was to functionalise the self-assembled nanostructures of P123 by amino acids and gold 
nanoparticles by a novel method. The reason behind functionalisation was to obtain a slow and 
sustained release profile of TQ over a longer period of time. Overall results demonstrated that 
the P123 Asp-Au TQ has the potential to be developed as a biocompatible nano-carrier for 
encapsulating TQ and other phytochemicals to enhance their therapeutic effect and their 
stability making them a successful line of treatment with low side effects.  
When pristine TQ was administered to cells at 10 μM, viability was decreased by ~20% and 
expression of E-cad was reduced very significantly. When the concentrations of the nano-
formulation were titrated on the basis of viability from levels of free TQ at 10 μM, a reduction 
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in expression was visible, with cell death remaining almost same as free TQ. The results 
indicated that low concentrations of TQ (low bioavailability) induced EMT in the cells. The 
thesis further suggested that the problem of TQ stability can be resolved by the use of different 
nano-formulations to increase its therapeutic efficacy against breast cancer. 
The overall study in this thesis, investigates a new mode of interaction of pristine TQ due to 
low stability and bioavailability while creating a path towards increasing its stability and 
efficacy using different types of nanoformulations.  
7.2 Future prospects  
 
In last few decades phytochemicals have gained a significant attention as natural products for 
treatment of various diseases. The interaction of natural phytochemicals in biological system 
has been extensively studied for anticancer activity and numerous signalling pathways have 
been identified. This thesis encompasses two major aspects which include elucidating the 
mechanistic aspect of TQ interaction in cancer cells at low or sub-toxic concentration and using 
nanoformulations to address the issue of low stability and bioavailability.  
The mechanistic aspect of TQ was studied with regards to reorganization of cytoskeleton and 
destruction of cadherin-catenin complex. However, phytochemicals such as TQ affect multiple 
signalling transduction pathways; hence in-depth evaluation at molecular and genetic level 
would be ideal to understand the effect of TQ.    
In order to improve the understanding on TQ’s mechanism, it requires genomic and proteomic 
profiling of cells after treatment of TQ. The main outcome from both can be used to deduce a 
systematic network of molecules affected by the application of TQ. Further knowledge could 
be enhanced by using a systems biology approach which involves the use of integration of large 
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data sets obtained from genomics, proteomics and transcriptomics to obtain a holistic view of 
complex interaction of molecules occurring in the cells [36-38].  
According to literature, quinones are known to exhibit mutagenicity. They are also known to 
cause irreversible/reversible genetic alterations thereby disrupt the functioning of DNA or 
cause mutations in the DNA [2, 39]. These mutations represent a threat to the human race with 
regards to cancer. Hence, epigenetic studies would help to reveal the useful markers affected 
by TQ which could provide the insight into new signalling pathways as well as identify the 
useful markers required for cancer diagnosis and pharmacological treatment.  
The second main aspect covered in the thesis is use of nanoformulations to address the issue 
of low bioavailability to improve its stability by encapsulation. The improvement in therapeutic 
efficacy of TQ not only depends upon TQ loading and release kinetics but also on the uptake 
of nanoformulations in the cells. In order to understand the TQ loaded nanoparticle interaction 
with cancer cells and delivery of its cargo, uptake studies could be performed. This could be 
done either by loading with fluorescent dye and tagging a fluorophore on the surface of the 
nanoparticle as rhodamine B or fluorescein isothiocyanate (FITC) [35, 40]. In case of P123 
amino acid micelles, the uptake studies can be performed by using transmission electron 
microscopy (TEM) as the polymeric micelles consist of gold nanoparticles formed on the 
surface. Gold nanoparticles are known to be promising contrasting agent and are known for 
their use in tagging antibodies in order to provide detection in TEM samples of cells.  
Recently, gold nanoparticles have attained a lot of importance as contrasting agents for 
computed tomography as they exhibit biocompatibility and high x-rays absorption coefficient 
[41, 42]. Hence, the P123 amino acid micelles applicability should be explored in medical 
imaging. With this added feature the micelles could be exploited for diagnostics and therapeutic 
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capabilities at the same time [43-45]. Thus, emerging as a versatile tool for exploitation in the 
field of theranostics. 
The future work can be focussed on the unique approach of conjugating one or more ligands 
specific to the receptors on cancer cells on either dendrimers or P123 amino acid micelles 
which can further increase the uptake, specificity and selectivity for cancer cells. 
Dendrimers and P123 amino acid micelles showed promising results in case of MCF-7 and 
MDA-MB-231 cells with much higher increase in therapeutic efficacy. It would be interesting 
to gain insight and further evaluate their bio-distribution in vivo in order to translate the drug 
delivery technology from bench to bedside. 
Overall work summarized in this thesis offers a vision to understand the mechanistic aspects 
of thymoquinone at sub-toxic concentration during low bioavailability and extenuating by 
using drug delivery carriers.  
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Chapter 2 
“Thymoquinone mediated lysosomal degradation of E-cadherin in breast cancer cell” 
Vishal Mistry, Ravi Shukla, Vipul Bansal. 
Chapter 3 
“Nanosuspension of Thymoquinone: Formulation, characterization and bio-evaluation” 
Vishal Mistry, Hitesh Kulhari, Deep Pooja, Ravi Shukla and Vipul Bansal. 
Chapter 4 
“Thymoquinone encapsulation in dendrimers enhances its efficacy towards breast cancer”  
Vishal Mistry, Hitesh Kulhari, Ravi Shukla and Vipul Bansal. 
Chapter 5 
“Self-assembled nanostructures of triblock copolymer-aspartate gold nanoparticles as TQ 
delivery vehicles with improved stability and therapeutic efficacy”  
Vishal Mistry, S.Periasamy, Hitesh Kulhari, Ravi Shukla and Vipul Bansal. 
 
